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ABSTRACT
Morgan, Brittney J. An Investigation of Enzymes Capable of Activating Cannabinoid
Prodrugs. Unpublished Master of Science thesis, University of Northern
Colorado, 2018.
The plant Cannabis sativa contains a class of terpenophenols called cannabinoids
which, in their active form, have been shown to have antiproliferative, anti-metastatic,
anti-angiogenic, and pro-apoptotic effects on several types of cancer cells both in vitro
and in vivo. Cannabinoids have been shown to not exert this apoptotic activity in healthy
cells and they do not elicit the usual side effects seen with conventional chemotherapies.
However, naturally occurring prodrugs from Cannabis must first be converted into the
active form to induce the apoptotic and other physiological activities. Although humans
do not possess the enzyme(s) necessary for this conversion, several different microbial
species have been shown to have enzymes capable of catalyzing reactions similar to that
required for activation of the cannabinoid prodrug(s).
This research focused on the isolation of the prodrug cannabidiolic acid (CBDA)
from Cannabis and screening of various microbial cell lines capable of enzymatic
conversion of CBDA to the active drug cannabidiol (CBD). This involved the
development of a preparative HPLC method for isolation of CBDA and an analytical
HPLC method for the monitoring of enzymatic prodrug conversion. Seven microbial
species were screened for CBDA decarboxylation activity of the prodrug from Cannabis.

iii

The cells were incubated with CBDA, and the substrate and resulting product(s) from
incubation were simultaneously extracted from the incubated cell suspension at different
time intervals and analyzed using HPLC. The Gram-negative bacterium Pseudomonas
putida was identified to possess this enzymatic activity and will be an ideal species for
gene isolation and further screening of the target enzyme. The results from this research
provide an alternative to the traditional mode of activating cannabinoid pro-drugs and a
new way to potentially control and monitor the effective dose of cannabinoids being
administered.
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CHAPTER I
INTRODUCTION
With origins that date back to ancient times, many botanical extracts utilized as
folk remedies have now been developed into modern day medicine. Acetylsalicylic acid
(e.g., aspirin) was synthesized from a compound that came from the bark of Willow trees
(Salix alba) which was used by many ancient cultures as a pain remedy before the
discovery of salicylic acid as the naturally occurring active drug (Mahdi, Mahdi, Mahdi,
& Bowen, 2006). More recently the plant Cannabis sativa, which has long been
cultivated and harvested for its medicinal qualities, has been of interest to the scientific
community. The first accounts of Cannabis used medicinally come from the world’s
oldest pharmacopoeia, the Pȇn-tsao Ching, which was compiled in 4,000 B.C. based
upon oral traditions (Li, 1974). Despite its historic prevalence, however, the primary
active compounds in the plant Cannabis sativa, phytocannabinoids, were not initially
characterized until 1964 (Gaoni & Mechoulam, 1964).
At least 150 different phytocannabinoid compounds, considered terpenophenols,
have been identified from Cannabis sativa over the past few decades (ElSohly & Gul,
2016). Of these compounds, the most abundant are Δ 9-tetrahydrocannabinolic acid
(THCA), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA) (Figure 1), Δ 9tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and cannabigerol
(CBG) (Figure 4) (Backer et al., 2009).
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Figure 1: Structures of Δ9-tetrahydrocannabinolic acid (THCA), cannabidiolic acid
(CBDA), and cannabigerolic acid (CBGA).
Initially, due to their lipophilic nature, it was assumed that cannabinoids exerted
their effects by acting on biological membranes (Mavromoustakos, Yang, &
Makriyannis, 1995); however, this hypothesis was challenged following the discovery of
an endogenous cannabinoid system along with endogenous agonists (mainly anandamide
and 2-arachidonoyl glycerol, termed endocannabinoids) of the cannabinoid receptors
(Pacher, Bátkai, & Kunos, 2006).
The two major cannabinoid receptors in the endocannabinoid system have been
classified as Cannabinoid Receptor Type 1 (CB1) and Cannabinoid Receptor Type 2
(CB2) (Pertwee, 2008a). The CB1 receptor is more responsive to psychoactive
cannabinoids, such as THC, than to non-psychoactive cannabinoids, such as CBD
(Matsuda, Lolait, Brownstein, Young, & Bonner, 1990). Interestingly, there is a high
concentration of CB1 receptors in the brain. The crystal structure of the human CB 1
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receptor was elucidated by Hua et al. in 2016, providing not only a further understanding
of how the endogenous ligands bind but also a rationale for CB 1 drug design.
Although CB2 receptors are found primarily in membranes of the immune system
cells, such as those found in lymph tissues, they have been observed as being more highly
expressed on various cancerous cells. Activation of G-coupled inhibitory proteins (G i)
associated with these cell membrane receptors leads to inhibition of adenylyl cyclase as
well as many other signaling transduction pathways that modulate cell function
(Alexander, Smith, & Rosengren, 2009). Cannabinoids, via these cannabinoid receptors,
have the ability to regulate cellular signaling pathways which are critical for cell growth
and survival. Therefore, cannabinoids may be useful in the treatment of cancer because
of the high concentration of CB2 receptors in tumor cell membranes (Alexander et al.,
2009). With the emergence of more research on the endocannabinoid system and the role
of cannabinoids as agonists in this system, the use of cannabinoids as therapeutic agents
has become an attractive prospect.
Phytocannabinoids from Cannabis sativa have been reported to possess a variety
of medicinal properties including antiproliferative activity in animal models toward
specific solid tumors such as brain, pancreas, breast, prostate, colon, liver, and lung
cancers (Massi et al., 2004). These antiproliferative properties are expressed when
receptors of the endocannabinoid system are bound by specific phytocannabinoids. For
example, CBD displays an unexpectedly high potency as an agonist of CB 1 and CB2 in
cells expressing these receptors; indeed, the manner which it interacts with CB 2 receptors
provides a possible explanation for CBD’s ability to interfere with immune cell
chemotaxis and migration (Pertwee, 2008b).
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Along with the ability of cannabinoids to inhibit tumor growth which has been
observed in vitro and in vivo in several mice models, cannabinoids have been observed to
demonstrate selective cellular toxicity, inducing cell death in vitro in human brain tumor
cells at concentrations that are not harmful to normal cells (Salazar et al., 2009). This
selective toxicity is significant because an effective anti-cancer treatment should induce
apoptosis in tumor cells while not effecting healthy cells. Many cancer treatments in
clinical use today do not possess this selective property and thus affect healthy cells
producing unwanted side effects in contrast to cannabinoid-based treatments which
potentially produce very few, if any, side effects (Robson, 2001). The potential for
treatments with this selective nature with minimal side effects makes cannabinoids the
interest in this study.
Currently, there are several commercial cannabinoid-based treatments available
which utilize this cannabinoid activity in the body including Sativex®, Marinol®, and
Epidiolex® (GW Pharmaceuticals, 2018). Sativex® is a THC-CBD-enriched, botanical
extract for treating moderate to severe symptoms of multiple sclerosis including pain and
spasm and was the first drug to have been approved by the FDA with two active
ingredients in a single drug. Marinol®, a synthetic THC analog, alleviates nausea and
emesis in cancer patients undergoing chemotherapy and has also been demonstrated to
mitigate anorexia and cachexia associated with AIDS or chemotherapy. The most current
drug approved by the FDA is the CBD-based drug Epidiolex® used to treat seizures
associated with Dravet syndrome and tuberous sclerosis (GW Pharmaceuticals, 2018).

5
In consideration of growing support for cannabinoids as safe, effective drugs
currently available for epilepsy, as well as research supporting cannabinoids as
candidates for targeted anti-cancer therapy, an efficient delivery system needs to be
developed to address any obstacles which may be present when proposing a cannabinoidbased drug. First, cannabinoids are synthesized in plants as the acidic form CBDA or
THCA, for example, which serve as precursors to the therapeutically-active forms CBD
and THC, respectively. To convert the physiologically-inactive acidic form from the
plant (termed the prodrug) to an active drug, the cannabinoid-based component must be
decarboxylated to remove its acidic functional group (Figure 2).

OH

O

OH

+ CO2

OH

HO

HO

CBDA

CBD

Figure 2: Decarboxylation of cannabidiolic acid (CBDA) to cannabidiol (CBD).
A simple way to decarboxylate these compounds is to heat them, usually
accomplished by smoking or baking Cannabis plant material. However, this is not an
ideal way to deliver a proper dose of the active drug to the site of the tumor. Active drugs
comprise only a small portion of the Cannabis sativa plant; thus when absorbed through
ingestion or inhalation most of the active drug will be distributed throughout the blood
stream and only a small amount of therapeutic agent will actually reach the site of the
tumor (Casarett & Doull, 2013). Additionally, if delivered in this manner one would
need to consider the psychoactive properties of ∆9 -THC, the concentration of which
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varies from each strain of the plant, and how it would affect adult and child patients
regarding cognitive function, reaction time, learning and memory functions.
Enzymatic decarboxylation of cannabinoids was explored in this study as an
alternative method to heating. While humans do not possess the enzyme(s) necessary to
catalyze the decarboxylation of cannabinoid compounds, several cell types, both
prokaryotic and eukaryotic, have been reported to possess enzymes capable of catalyzing
this specific reaction using substrates with functional groups similar to the cannabinoids
(Grant & Patel, 1969; Santha, Rao, & Vaidyanathan, 1996; Kirimura, Gunji, Wakayama,
Hattori, & Ishii, 2010; Snini et al, 2013). Many of these cell lines reported in the
literature were explored in this study to identify an organism with the appropriate enzyme
capable of this decarboxylase activity. Those organisms which exhibit the most potential
will be considered for gene isolation of the target enzyme which could then be transfected
into a eukaryotic cell of choice. The modified cell would then be encapsulated using
Cell-in-a-Box® cellulose-based live cell encapsulation technology (PharmaCyte, 2017)
and injected directly upstream from a tumor. This would allow for the appropriate
dosage of a highly-targeted therapeutic drug to be converted directly to the active drug at
the site of the tumor, making it an attractive cancer treatment.
To identify an enzyme that could activate the naturally occurring prodrug CBDA
to its active drug form CBD, four different bacterial species and three fungal species were
screened for activity; these species included Enterobacter (Klebsiella) aerogenes,
Pseudomonas putida, Klebsiella pneumonia, Bacillus subtilis, Aspergillus clavatus,
Aspergillus niger, and Penicillium chrysogenum. The microbial cells, both intact and
lysed, were incubated with the cannabinoid prodrug. The cannabinoid substrate and
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product(s) were simultaneously extracted from the incubated cell suspension at
appropriate time intervals during incubation and analyzed using high-performance liquid
chromatography (HPLC). The retention times of peaks in the chromatograms were
compared to known standards to determine if the prodrug was activated by the species
assessed.
In this study, identification and quantification of cannabidiol was assessed
through the use of HPLC. The most common methods for qualitative and quantitative
analysis of phytocannabinoids from Cannabis sativa include GC/FID and GC/MS (Klein,
2015); however, although these methods are rapid and well established, these methods
are not useful for heat-labile compounds which can be decarboxylated via heat. Instead,
an analytical HPLC method for monitoring conversion of CBDA to CBD and a
preparatory HPLC method for isolation of CBDA from crude Cannabis extract were
developed. This allowed for the initial steps of development of an enzyme-driven,
cannabinoid-based drug to be performed in-house, from plant to active drug.

8

CHAPTER II
REVIEW OF LITERATURE
Cannabinoids can be classified into three major categories; endocannabinoids,
phytocannabinoids, and synthetic cannabinoids (Pertwee, 2008a). Endogenous
endocannabinoids are made in animals, including humans; in contrast, phytocannabinoids
are plant-derived products from Cannabis while synthetic cannabinoids are laboratory
produced. Although a brief mention of endocannabinoids is presented, this review
focuses on the structure, function, and biological activity of phytocannabinoids. In
addition, a broad review of many different in vitro and in vivo studies on various cancer
cell lines is presented as a rationale for cannabidiol as a targeted cancer chemotherapeutic
agent. Enzymatic conversion of cannabinoid model compounds is also discussed in
support of an enzyme-based conversion of the inactive prodrug cannabidiolic acid to
cannabidiol. Finally, Cell-in-a-Box® technology is discussed as a potential mechanism
of delivery using a genetically-engineered cell containing the gene necessary for an
enzyme capable of catalyzing the conversion of prodrug to active drug.
Cannabinoids
Phytocannabinoids from Cannabis sativa are synthesized in their acidic forms,
from isopentyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), the
precursors of all terpenoids (Fellermeier, Eisenreich, Bacher, & Zenk, 2001). Although
believed to be biosynthesized via the mevalonate pathway prior to the 1990s, it has been
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suggested that the precursors IPP and DMAPP are derived predominantly via the
deoxyxylulose phosphate pathway (Eisenreich, Rohdich, & Bacher, 2001). An overview
of the biosynthesis of major cannabinoids from these precursors is shown in Figure 3. In
general, IPP (1) and DMAPP (2) are condensed to form geranyl diphosphate (3) which
then combines with olivetolic acid (4) to form cannabigerolic acid (5) from which the
remaining cannabinoids are derived. Due to their origin from these two isoprene
derivatives and their phenolic properties, cannabinoids can be categorized as
terpenophenols.

Figure 3: Biosynthesis of cannabichromenic acid (6), tetrahydrocannabinolic acid (7),
and cannabidiolic acid (8) from the precursors IPP (1) and DMAPP (2). The
intermediates geranyl diphosphate (3), olivetolic acid (4), and cannnabigerolic acid (5)
are also shown. From Fellermeier et al. (2001), used with permission (Appendix C).
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Currently, over 150 cannabinoids have been characterized from Cannabis sativa
(ElSohly & Gul, 2016). These cannabinoids can be categorized based on structural
similarities as tetrahydrocannabinols (THCs), cannabidiols (CBDs), cannabinols (CBNs),
cannabigerols (CBGs), cannabichromenes (CBCs), and cannabinodiols (CBNDs), the
most abundant of which are THCs, CDBs, and CBNs. Those which are deemed
structurally unique cannabinoids are categorized as miscellaneous (ElSohly & Slade,
2005). Structures of representative compounds from each category are shown in Figure
4.

Figure 4: Representative structures of THCs, CBDs, CBNs, CBGs, CBCs, and CBNDs.
From Thakur, Duclos, & Makriyannis (2005), used with permission (Appendix C).
Although there is much structural variance among these six major categories of
cannabinoids, most are composed of 21 carbons which includes an n-pentyl chain on C-3
(THCs) or 5’-C (CBDs) of the aromatic ring. The variability of functional group
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moieties accounts for the difference in physiological activity among cannabinoids
(Thakur et al., 2005). This variability in structure also causes chemical nomenclature of
certain cannabinoids to differ, for example the numbering of CBD compared to THC.
These two structures are closely related, and CBD has been shown to cyclize into THC
under acidic conditions (Gaoni & Mechoulam, 1964); however, due to their differences in
functionality, they are numbered differently. Numbering for THC is therefore determined
by a pyran ring; CBD relies on a terpene ring for numbering priority (Mechoulam &
Hanuš, 2002). These numbering systems are given in Figure 5.

Figure 5: Numbering system for THC and CBD.
The remainder of this review will focus predominately on the related
cannabinoids CBDA and CBD. CBD is distinguished by its aromatic and terpene rings,
which lay nearly perpendicular to each other. Two independent forms, which differ
mainly in the conformation of the pentyl side chain, were noted by Jones et al. (1977)
when elucidating the crystal structure. The major torsion-angle difference is for the C
(5’)-C(1’’)-C(2’’)-C(3’’), which is -57.2 and 179.2° for forms 1 and 2, respectively.
Also, the benzene ring in the first form is planar and all substituents are coplanar while in
the second form the aromatic ring is twisted slightly with a torsion angle of -4.1° and the
3’-OH bent slightly out of the plane of the ring. CBDA differs from CBD by a
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carboxylic acid group on the 6’ carbon ortho to the phenolic hydroxyl (Mechoulam &
Hanuš, 2002). The decarboxylation of CBDA allows it to act as a prodrug where, upon
decarboxylation, different biological effects can be noted (Ligresti, 2006).
Cannabinoid Physiology
The ability of cannabinoids to regulate the endocannabinoid system and the role
of its receptors has been supported in numerous studies. Shortly after the
characterizations of several phytocannabinoids, starting with the characterization of ∆ 9THC by Raphael Mechoulam in the 1960s, researchers began to speculate how
cannabinoids exert their effects in the body. Although it was originally assumed that
cannabinoids exerted their effects by acting on biological membranes due to their
lipophilic nature (Mavromoustakos et al., 1995), it was later discovered that the
biological effects exerted by cannabinoids is facilitated through binding to endogenous
cannabinoid-like receptors (Fonseca, Costa, Almada, Correia-Da-Silva, & Teixeira,
2013). This is not to say that cannabinoids only act upon the endogenous
endocannabinoid system, merely that it is the primary mode of action.
Two major cannabinoid receptors of the endocannabinoid system have been
identified as Cannabinoid Receptor Type 1 (CB1) and Cannabinoid Receptor Type 2
(CB2) (Pertwee, 2008a). The crystal structure of the human CB1 receptor was elucidated
by Hua et al. in 2016. The characterization of these receptors allowed for a more indepth understating of ligand-receptor interactions and helps provide rationale for drug
discovery. CB1 receptors are highly expressed in nociceptive areas in the brain, the
cerebellum, limbic system, and basal ganglia. This location of the CB1 receptor makes it
more responsive to psychoactive cannabinoids, such as THC, than to non-psychoactive
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cannabinoids, such as CBD (Matsuda et al., 1990). Those receptors located in the brain
are sparse in density in lower brainstem areas controlling cardiovascular and respiratory
function, which may explain why high doses of cannabinoids are not lethal (Herkenham
et al., 1990). CB1 receptors have also been detected in spleen, eye, uterus, and testes
(Guzmán, 2003).
In contrast, the CB2 receptors are found mainly in peripheral tissues and tissues of
the lymph nodes, tonsils, and spleen. Due to these locations, CB 2 is mainly a peripheral
immunomodulation receptor with an important role in mediating pain, inflammation, and
physiological defense (Pacher et al., 2006). The CB2 receptor has also been observed in
tumor cells. Both CB1 and CB2 receptors belong to the G-protein-coupled family of
receptors and thus are mediated by activation of Gi/o alpha subunits (Turu & Hunyady,
2010). Activation of these G-coupled cell-membrane proteins may lead to inhibition of
adenylyl cyclase as well as many other signaling transduction pathways that modulate
cell function (Alexander, Smith, & Rosengren, 2009).
Shortly after the identification of the CB1 and CB2 receptors, research expanded
from just studying cannabinoids in marijuana to looking for cannabinoid-like compounds
produced in the body that act on the endogenous cannabinoid receptors. The endogenous
agonists anandamide and 2-arachidonoyl glycerol were discovered, revealing that the
primary physiological function of the endocannabinoid system was to bind these
endogenous ligands (Pacher, Bátkai, & Kunos, 2006). These endogenous ligands
(endocannabinoids) are made within the cell and are synthesized on-demand throughout
the body from precursors in lipid membranes (Alger, 2013), so they can be used exactly
when and where they are needed in the body, rather than being packaged and stored
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similar to other signaling molecules. Endocannabinoids travel in a retrograde fashion to
inhibit neurotransmitter release, making the main function in the brain to attenuate
release of neurotransmitters (Guzmán, 2003). These receptors, along with the
endocannabinoids themselves and their regulatory enzymes, make up the
endocannabinoid system which is present in many chordates of the animal kingdom
(Elphick, 2012). Activation of this system is associated with various processes including
regulation of appetite, motor activity, memory, learning, emesis, and nociception
(Fernández-Ruiz et al., 2007). More generally, it can be said that the role of the
endocannabinoid system which has been observed is a role in homeostasis by controlling
metabolic functions such as energy storage and transport and immune function (Pagotto,
Marsicano, Cota, Lutz, & Pasquali, 2006).
In a 1998 report by Marzo et al., the functions of endocannabinoids were
summarized as aids to “relax, eat, sleep, forget, and protect” with a focus on the
endocannabinoids and their relation to the sensation of hunger. The amount of leptin, a
hunger-inhibiting molecule, was shown to be inversely correlated with the number of
endocannabinoids produced suggesting a relationship between the endocannabinoid
system and appetite. If the endocannabinoid system is stimulated (by endo- or
phytocannabinoids), an individual will have less leptin, and therefore will feel hungrier.
These results interestingly align with anecdotal evidence from recreational Cannabis
users who self-reported feeling hungrier when ingesting more and more Cannabis.
Unsurprisingly because of the large number of cannabinoid receptors in the brain,
the endocannabinoid system is also reported to be involved in the regulation of memory
(Alvares, Genro, Diehl, & Quillfeldt, 2008). A common effect self-reported by Cannabis
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users is short-term memory impairment. In 2009, Mazzola et al. reported a significant
impairment in the memory of rats when Δ9-THC was injected intra-peritoneally at
concentrations of 3.0, 5.0, and 6.0 mg/kg 30 minutes prior to a passive-avoidance task.
Long term potentiation in the hippocampus, a process essential for formation of storage
of long-term memory, has been shown to be suppressed in mice treated with THC
(Hampson & Deadwyler, 1999). The role of the endocannabinoid system in memory is
also supported by the observation that CB1 knockout mice show enhanced memory and
long-term potentiation (Jiang, 2005). Although it is generally agreed upon that
cannabinoids do have a regulatory role in memory, contradictory information on whether
these effects impair or improve different phases of the memory processes exist
simultaneously. Impairments in object recognition have been linked to dysregulation of
the glutamatergic system (Nilsson, Hansson, Carlsson, & Carlsson, 2007) as well as
hippocampal and para hippocampal dysfunction (Fernández-Ruiz et al., 2007).
Interestingly, a study found that CBD interacts with the glutamatergic system (Hallak et
al., 2011); CBD augmented the effects of an N-methyl-d-aspartate (NMDA) receptor
antagonist in a human study, a receptor which is associated with memory and learning
impairments. CBD was also shown to be protective against glutamate neurotoxicity
(Hampson & Deadwyler, 1999). Finally, memantine, another NMDA receptor antagonist,
improved object recognition in a transgenic Alzheimer Disease mouse model (Scholtzova
et al., 2008) suggesting that CBD may improve recognition memory via the glutamatergic
pathway. Although much has been learned about the endocannabinoid system, as of yet,
it is still incompletely understood.
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Cannabidiol and Cancer
This thesis research is grounded in much evidence from prior research into the
effectiveness of cannabinoids, and more specifically cannabidiol, as cancer treatments.
Cannabidiol is of specific interest as a cancer drug because it has many of the same
antiproliferative effects as other cannabinoids without the psychotropic effects (Izzo,
Borrelli, Capasso, Di Marzo, & Mechoulam, 2009). Cannabinoids could be useful in the
treatment of cancer due to their ability to regulate cellular signaling pathways critical for
cell growth and survival (Alexander et al., 2009). Expression of CB 1 and CB2 receptors
has been found in many types of cancer cells, although this does not necessarily correlate
with the expression of these receptors in the tissue of origin (Guzmán et al., 2006). The
fact that these receptors are upregulated in cancerous tissue and not in the surrounding
tissue may explain the observation by McAllister et al. (2005) that cannabinoids can
selectively inhibit proliferation and induce cancerous cell death at concentrations that do
not harm normal cells.
The expression of CB1 and CB2 receptors in tumors of patients with hepatocellular
carcinoma was studied by Xu et al. (2006). Patients were treated with embolization
therapy to essentially starve the cancerous tumors of blood flow and essential nutrients.
Patients then underwent a hepatectomy and liver samples were preserved for analysis.
Their study concluded that when higher numbers of CB 1 and CB2 receptors are expressed
in cancerous tissue, there is a correlated improvement in prognosis in patients with
hepatocellular carcinoma (Xu et al., 2006) and potentially many other cancerous cell
lines. Therefore, cannabinoids may be useful in the treatment of cancer because of the
high concentration of cannabinoid receptors in tumor cells (Alexander et al., 2009) which
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are selectively targeted by cannabinoids. Studies on the effect of CBD on prostate,
breast, glioma, and other cancer cell lines are reviewed later in this section.
In general, activation of CB1 by cannabinoids minimizes membrane
depolarization on presynaptic cells by inhibiting voltage-gated Ca 2+ channels and
activation of voltage-gated K+ channels (Turu & Hunyady, 2010). The result is a
decrease in neurotransmitter release from presynaptic cells. Activation of the
cannabinoid receptors in cancer cells has been reported to increase the levels of ceramide
which has been shown to activate a mitogen-activated protein kinase (MAPK) pathway
known as the extracellular-signal-regulated kinase (ERK) survival pathway (EllertMiklaszewska, Grajkowska, Gabrusiewicz, Kaminska, & Konarska, 2007; Ozaita,
Puighermanal, & Maldonado, 2007) . Activation of the ERK pathway usually results in
cell proliferation, however continual stimulation causes arrest of the cell cycle and
apoptosis. Cannabinoids have also been shown to exert anti-proliferative effects on
cancer cells by causing an arrest of the cell cycle through the inhibition of adenylyl
cyclase (Fonseca et al., 2013). This pathway can occur through activation of either CB 1
or CB2 since they are both coupled to inhibitory G-proteins. Inhibition of adenylyl
cyclase leads to lower concentrations of intracellular cAMP thus decreasing the activity
of protein kinase A (PKA) and also activating the ERK pathway similar to the effect by
increased levels of ceramide (Figure 6).
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Figure 6: Schematic of CB1 and CB2 cellular signaling. From Katchan, David, and
Shoenfeld (2016), used with permission (Appendix C).
Other potential pathways include transient receptor potential cation channel,
subfamily V, member 1 (TRPV1) activation, downregulation of the vascular endothelial
growth factor (VEGF) pathway, production of reactive oxygen species (ROS), induction
of endoplasmic reticulum (ER) stress, and the activation of both intrinsic and extrinsic
apoptotic pathways (Ramer, Merkord, Rohde, & Hinz, 2012). The mechanism of tumor
cell inhibition produced by CBD was shown to depend on the type of cancer cell being
analyzed (Massi, Solinas, Cinquina, & Parolaro, 2013). Importantly, of the cannabinoids
CBD seemed to involve direct TRPV1 activation and/or CB 2 indirect activation (via fatty
acid amide hydrolase), as well as induction of oxidative stress (Ligresti, 2006). Due to its
many mechanisms of action, some of which are noted in Figure 7, cannabidiol is of
interest in treating a variety of cancers. Activation of CB receptors can be responsible for
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the increase in levels of ceramide or decrease of cAMP level via inhibition of adenylyl
cyclase, both events lead to apoptosis mediated by caspase activities. Also, the ability for
TRPV receptors activated by cannabinoids to cause an increase in the level of ROS and
oxidative stress which leads to apoptosis has been observed. Although each mechanism
may be activated differently, the process is highly interconnected and each event will lead
to the same end effect, tumor cell death.

Figure 7: Schematic of various cell-death pathways potentially regulated by CBD. From
Calvaruso, Pellerito, Notaro, & Giuliano (2012), used with permission (Appendix C)
Prostate cancer is the most common non-skin cancer among men in the United
States (National Cancer Institute, 2017). The in vitro antitumor and anti-inflammatory
activities of CBD in human prostate cancer cell lines were investigated by Sharma,
Hudson, Adomat, Guns, & Cox (2014). Treatment of human prostate cancer cell lines
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LNCaP and PC3 with Cannabis extracts containing 20–60 µg/mL CBD showed
negligible activity at the lowest concentration (20 µg/mL) and massive induction of
apoptosis at the highest concentration (60 µg/mL). This supports the need for a targeted
approach to delivery and precision dosing when using CBD as a therapeutic drug.
Also examined in the Sharma et al. (2014) study was the effect of a Cannabis
extract on androgen receptor transcripts. Because over-expression of androgen receptors
in prostate cancer cells may promote cell growth, inhibiting this expression with the use
of CBD may prove beneficial in preventing tumor growth. Treatment of LNCaP cells
with Cannabis extract prepared in dimethyl sulfoxide (DMSO) containing 20, 40, 60, and
70 µg/mL CBD resulted in a marked decrease in androgen receptor expression when
assessed at 24 hours post treatment. Although a significant decrease in expression was
observed at all concentrations of CBD, the highest concentration produced the largest
decrease in androgen receptor expression.
Additional studies of human prostate cancer cells in vitro and in vivo using mouse
models found that the CB2 receptor was involved in the inhibition of prostate cancer cell
growth in both experimental models (Olea-Herrero, Vara, Malagarie-Cazenave, & DíazLaviada, 2009). Petrocellis et al. (2012) studied the effects of several pure cannabinoids
(CBC, CBD, CBG, CBN, CBDA, CBGA, CBDV (cannabidivarin), CBGV
(cannabigevarin), THC, THCA, THCV (∆9-tetrahydrocannabivarin), THCVA (∆9tetrahydrocannabivarin acid)) and those in Cannabis extracts on different human prostate
carcinoma cell lines both in vitro and in vivo. Of the pure cannabinoids studied, CBD (1–
10 µM) was the most effective inhibitor of tumor growth in vitro. In vivo studies were
done with a Cannabis extract which contained 64.4% (w/w) CBD since it proved to be
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even more potent than pure CBD alone when evaluating cell viability via an MTT assay
in another portion of the study. Indeed, when the extract was administered to tumors
generated in athymic mice from LNCaP cells, the growth of these tumors was reduced
(Petrocellis et al., 2012).
Breast cancer is the most common cancer in women, regardless of race or
ethnicity, in the United States (National Cancer Institute, 2017). Several cannabinoids
were screened for their ability to reduce cell proliferation of different breast tumor cell
lines (MCF7 and MDA-MB-231) in vitro and in vivo in a mouse model by Ligresti
(2006). CBD exhibited the highest potency of cannabinoids studied, with IC 50 values
being 8.2 ± 0.3 µM (MCF7) and 10.6 ± 1.8 µM (MDA-MB-231). CBD selectively
inhibited the growth of these two breast cancer cell lines in vitro at a range of
concentrations (2.0-25 µM). Cannabidiol at a concentration similar to its IC 50 did not
affect the vitality of nontumor cell lines. Only at a concentration as high as 25 µM,
which inhibited 100% of tumor cell growth, was viability of non-cancerous cells affected.
Data regarding the extent to which the healthy cells were affected were not noted in the
study. Mice with xenograft tumors obtained by subcutaneous injection of human MCF7
and MDA-MB-231 breast carcinoma cells were treated in vivo with either pure
cannabidiol (5 mg/kg) or a cannabidiol-rich extract (6.5 mg/kg) and exhibited
significantly smaller tumors in comparison with control mice.
In addition to confirming the in vitro observation by Ligresti (2006) of a reduction
in proliferation of the human breast cancer cell line MDA-MB-231 when exposed to
CBD, McAllister et al. (2007) reported a reduction in cancer cell proliferation in an
additional breast cancer cell line, MDA-MB-436. Cells were treated with 0.1, 1.0 or 1.5
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µM solutions of CBD for three days. Because the 1.5 µM solution was the most
antiproliferative, the McAllister group examined the inhibitory effect of CBD at this
concentration on Id-1 expression. Id-1, an inhibitor protein of basic helix-loop-helix
transcription factors, has been shown to be a key regulator of the metastatic potential of
breast and additional cancers (Benezra, Davis, Lockshon, Turner, & Weintraub, 1990).
McAllister et al. (2005) previously demonstrated that reducing Id-1 led to significant
reductions in breast cancer cell proliferation in vitro suggesting that reducing Id-1
expression could be a therapeutic strategy. Their 2007 study found that after a three-day
treatment with CBD (1.5 µM, daily), the mRNA transcription of the Id-1 gene was
significantly inhibited. Minn et al. (2005) had previously shown that CBD regulated the
expression of key genes involved in the control of cell proliferation and invasion via the
down-regulation of Id-1. This down-regulation may be one of the mechanisms by which
CBD can reduce tumor aggressiveness. More recently, it was discovered that the Id-1
down-regulation was mediated by the up-regulation of extracellular-signal-related kinase
(ERK) phosphorylation which produces the active isoform of the ERK protein
(McAllister et al., 2012). Previously mentioned studies already showed that over
stimulation of the ERK pathway contributed to arrest of the cell cycle and apoptosis,
further supporting the inhibitory action of CBD through the ERK pathway.
An in vitro study which demonstrated the concentration-dependent nature of CBD
as an effective breast cancer treatment was reported by Shrivastava, Kuzontkoski,
Groopman, & Prasad (2011). These researchers found that CBD induced apoptosis in
human breast cancer cell lines MDA-MB-231, MCF-7, SK-BR-3, and ZR-75-1 in a
concentration-dependent manner (Figure 8). Moreover, it was found that at these
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concentrations, CBD had little effect on MCF-10A cells, a non-tumorigenic human
mammary cell line. These studies support the desirability of CBD as an anticancer agent
by demonstrating a selective toxicity for breast cancer cells.

Figure 8: Cell survival (as measured by an MTT assay) of various breast cancer cell lines
treated with increasing concentrations of CBD for 24 hours. From Shrivastava et al.
(2011), used with permission (Appendix C).
Gliomas, or tumors of glial origin, are notably aggressive forms of cancer to
which traditional forms of treatment such as radiation and chemotherapy are generally
unresponsive (Philip-Ephraim, Eyong, Williams, & Ephraim, 2012). In a study by Massi
et al. (2004), CBD (25 µM) was demonstrated to be effective in inhibiting U87-MG and
U373 human glioma cell proliferation in vitro while not affecting healthy glial cells. In
vivo treatment with CBD significantly reduced tumor growth of subcutaneously
implanted U87 human glioma cells in mice when administered at a dose of 0.5 mg per
mouse. In their study, it appeared that the addition of CBD to cell culture media during
in vitro studies led to a dramatic drop of mitochondrial oxidative metabolism and
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viability in the glioma cells. When adding the antioxidant α-tocopherol at a
concentration of 10 µM the antiproliferative effect of CBD was significantly prevented.
Inhibitory effects were observed more rapidly at concentrations close to their IC 50 values
with effects from CBD (25 µM) observed at 24 hours as compared to THC (1 µM)
observed within 2-5 days as reported by Sanchez et al. (1998)
In a study by Cianchi et al. (2008), the cytotoxic effect of N-cyclopentyl-7methyl-1-(2-morpholin-4-ylethyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide (CB13), a
synthetic CB2 agonist, was investigated in vitro using the four colon cancer cell lines
HCT8, SW480, HCA7, and HCT15 which had previously been reported to express the
CB2 receptor. The results of the study showed the growth of all cell lines was inhibited in
a concentration-dependent manner. The CB2 agonist also reduced growth of colon cancer
cells in vivo in a mouse model (Cianchi et al., 2008). Additionally, an extract of Cannabis
sativa with a high content of CBD was demonstrated to reduce proliferation in colorectal
cancer cells but not in healthy cells in a study by Romano et al. (2013). Proliferation was
evaluated by an MTT assay in both healthy and cancerous cells at concentrations of CBD
ranging from 0.3-5 µM CBD for 24 hours. Twenty percent inhibition of tumor cell
growth was reported with the highest concentration of CBD.
An in vivo study using athymic nude mice revealed a significant inhibition of
A549 lung tumor metastasis in animals treated with a dose of 5 mg/kg CBD every 72
hours for 28 days as compared to vehicle-treated controls. The number of metastatic
lesions in mice treated with CBD was one nodule after 28 days while the number of
nodules in mice treated with only the vehicle was six, yielding an 84% inhibition of
metastasis (Ramer et al., 2012).
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Enzymatic Decarboxylation
The carboxylic acid group ortho to the hydroxyl group on the aromatic ring of
CBDA must first be removed to elicit the desired physiological effects (Ligresti, 2006).
Many studies have reported the expression of an enzyme capable of catalyzing the
decarboxylation of phenolic carboxylic acids and other structurally similar acids by
several eukaryotic and prokaryotic species which include many from the genera
Pseudomonas, Klebsiella, Bacillus, Aspergillus, and Penicillium . In order to prioritize
substrates based on similarity to CBDA, they were organized into four categories with
Category 1 being the most similar and Category 4 being the least similar to the phenolic
carboxylic acid moiety of CBDA. These compounds were of interest because of their
similarity of the aromatic ring moiety, which interacts with the catalytic domain of these
decarboxylase enzymes, to the aromatic moiety of CBDA. For proper enzyme-substrate
binding to occur, there must be similarity between compounds so that important regions
of the binding site can interact properly with the substrate in order for the desired reaction
to occur.
Substrates such as salicylic acid, 6-methylsalicylic acid, 2,3-dihydroxybenzoic
acid and gentisic acid (2,5-dihydroxybenzoic acid) have hydroxyl groups ortho to the
carboxyl group, making them similar in structure to CBDA. Structures of these Category
1 substrates are presented in Figure 9. Cell lines capable of catalyzing decarboxylation of
these Category 1 substrates are reported below.
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Figure 9: Structures of Category 1 substrates.
Bacillus subtilis will express padC and bsdBCD genes when induced with
salicylic acid (Duy et al., 2007). PadC encodes for a phenolic acid decarboxylase (PAD)
while the bsdBCD operon encodes for phenylacrylic acid decarboxylase B and 4hydroxybenzoate decarboxylase C and D (Duy et al., 2007). Salicylic acid, a Category 1
substrate, was unsurprisingly decarboxylated to phenol by the phenolic acid
decarboxylase from padC but also was decarboxylated by the phenylacrylic acid
decarboxylase encoded by bsdBCD even though salicylic acid is not, in fact, a
phenylacrylic acid (Duy et al., 2007). However, it is known that genes for these enzymes
are down-regulated when stress is absent (Duy et al., 2007) and so induction was
necessary.
Trichosporon moniliform was shown to produce the enzyme salicylic acid
decarboxylase, which will catalyze the decarboxylation of not only salicylic acid but
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other carboxylic acids as well (Kirimura et al., 2010). The enzyme also catalyzed the
decarboxylation of b-resorcylic acid (2,4-dihydroxybenzoic acid) producing resorcinol
(1,3-dihydroxybenzene), c-resorcylic acid (2,6-dihydroxybenzoic acid) producing
resorcinol, 2,3-dihydroxybenzoic acid producing catechol (1,2-dihydroxybenzene), and
4-aminosalicylic acid producing 3-aminophenol.
Multiple fungal representatives have been reported to express a variety of
decarboxylases. A well-classified enzyme transiently expressed in Aspergillus recognizes
6-methylsalicylic, a substrate containing a carboxylic acid ortho to a phenolic hydroxyl
and a carbon side chain on C-6 which would be analogous to the pentyl chain on C-5’ of
CBD. The gene PatG, encoding this enzyme, is expressed by many fungi including
Aspergillus clavatus, Aspergillus giganteus, and Aspergillus longivesica as well as
Byssochlamys nivea, and Penicillium expansum (Snini et al., 2013).
The non-oxidative decarboxylation of 2,3-dihydroxybenzoic acid (2,3-dHBA) to
catechol is catalyzed by the enzyme 2,3-dihydroxybenzoic acid decarboxylase (2,3dHBAD). This enzyme is produced by several Aspergillus fungi including Aspergillus
oryzae and Aspergillus niger. Stable at physiological pH, dHBAD from Aspergillus
shows high specificity towards 2,3-dHBA and does not decarboxylate its analog 2,3,4trihydroxybenzoic acid (2,3,5-THBA). Interestingly, dHBAD from Trichosporon
cutaneum exhibited a broad substrate specificity and decarboxylated 2,3,5-THBA unlike
dHBAD from the Aspergillus species (Santha et al., 1996).
Halvorson (1963) demonstrated that a species of Aspergillus successfully
decarboxylated 2,4-dihydroxybenzoic acid to form resorcinol as an intermediary step in
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the metabolism of 2,4-dihydroxybenzaldehyde. The 2,4-dHBA was metabolized to form
resorcinol after 17 days and was completely metabolized after 29 days.
Category 2 substrates such as 3,4,5-trihydroxybenzoic acid (gallic acid), 3,4dihydroxybenzoic acid (o-protocatechuic acid), and 4-hydroxybenzoic acid (phydroxybenzoic acid) (Figure 10) have a phenolic hydroxyl para to the carboxylic acid
group but lack the ortho hydroxyl group. Decarboxylases for these Category 2 substrates
are still of interest, however, due to the variability of enzyme specificity.

Figure 10: Structures of Category 2 substrates.
An enzyme able to decarboxylate o-pyrocatchuic acid (3,4-dihydroxybenzoic
acid), a Category 2 substrate, was purified from a member of the Aspergillus genus,
Aspergillus niger (Subba, Moore, & Towers, 1967). Klebsiella aerogenes, previously
known as Enterobacter aerogenes, expresses p-hydroxybenzoic acid decarboxylase
(PHBD) which decarboxylates gentisic acid (Category 1), p-hydroxybenzoic acid (PHB),
gallic acid (3,4,5-trihydroxybenzoic acid), and protocatechuic acid. Two days were
required to decarboxylate a majority of PHB, gallic acid, and protocatechuic acid and
four days for gentisic acid. A permeability barrier was observed for PHB due to the
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increase in activity between intact cells and those which had been lysed with sonication.
However, the optimum conditions for this enzyme (pH 6) was below human
physiological pH (Grant & Patel, 1969).
Nakajima, Otani, & Niimura (1992) isolated K. pneumoniae and Streptococcus
faecalis for the study of decarboxylase enzymes. In their study, they were able to
demonstrate that, at an optimal pH of 6, K. pneumoniae possessed an enzyme capable of
catalyzing the decarboxylation of gallic acid, a Category 2 substrate. Similarly, a
decarboxylase enzyme from S. faecalis was able to decarboxylate both gallic acid and
protocatechuic acid. Optimal conditions for this decarboxylase were found to be a pH of
6.6 and a temperature of 45 °C. Researchers were able to show that for every one
molecule of gallic acid, one molecule of 1,2,3-trihyroxybenzene was formed, suggesting
a 1 to1 relationship between the substrate gallic acid and its decarboxylated product from
the decarboxylase enzyme partially purified from S. faecalis.
Three strains of Lactobacillus brevis were shown to decarboxylate gallic and
protocatechuic acid (Curiel, Rodríguez, Landete, Rivas, & Muñoz, 2010). Cultures were
incubated with a variety of 1 mM phenolic acids for 10 days at 30 °C to induce the
decarboxylase. Only those incubated in the presence of gallic acid decarboxylated gallic
acid and those incubated in the presence of protocatechuic acid decarboxylated
protocatechuic acid. Following the observation of decarboxylase activity from L. brevis,
a phenolic acid decarboxylase (PAD) gene was identified, cloned and characterized by
Landete et al. (2010) showing an optimum activity at pH 6 and 22 °C.
Compounds which have well-characterized decarboxylases but are lacking much
of the structural similarity to CBDA as in Category 1 and 2 are classified as Category 3
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substrates such as p-coumaric acid, ferulic acid, and caffeic acid (Figure 11), all of which
are derivatives of cinnamic acid.
Decarboxylases encoded by PadC in Bacillus subtilis were shown to display
substrate-specificity for decarboxylation of ferulic, p-coumaric, and caffeic acid. These
three acids are the three substrates of PAD (Duy et al., 2007). Studies from Cavin,
Dartois and Divies (1998) showed that induction of the PAD enzyme must occur for
decarboxylase activity to be observed in B. subtilis. Cell cultures were induced with
ferulic, p-coumaric, and caffeic acid. All substrates were shown to induce decarboxylase
activity, with caffeic acid having the lowest activity.

Figure 11: Structures of Category 3 substrates.
Category 4 encompasses miscellaneous substrates which have the least structural
similarities to CBDA. A mixed culture of marine bacteria isolated from marine sediment
(ON-7), Bacillus subtillis (Strain FO) and Pseudomonas testosterone were all cultured to
examine the metabolism of phthalic acids (Taylor & Ribbons, 1983). The mixed culture
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ON-7 was incubated with various phthalic acids for 4 hours at 30 °C. The culture was
able to decarboxylate phthalic acid, 4-hydroxyphthalic acid, 3-fluorophthalic acid, 4chlorophthalic acid, and 4,5-dihydroxyphthalic acid (Figure 12). B. subtilis was also
incubated with various phthalic acids for 20 hours at 30 °C and was able to decarboxylate
all substrates except the 4,5-dihydroxyphthalic acid. The P. testosterone culture was also
incubated with phthalic acids for 24 hours at 30 °C; however, this cell line only
decarboxylated 4-hydroxyphthalic acid and 4,5-dihydroxyphtalic acid.

Figure 12: Structures of Category 4 substrates.
An enzyme which has been shown to remove the carboxylic acid ortho to a
hydroxyl group from 1,2-dihydro-1,2-dihydroxybenzoic acid (Figure 12) is 1,2-dihydro1,2-dihydroxybenzoic acid dehydrogenase (Reiner, 1971). This enzyme catalyzes the
final step in the conversion of 1,2-dihydro-1,2-dihydroxybenzoic acid to catechol and has
been characterized from Pseudomonas putida, Pseudomonas cepacian, Acinetobacter
calcoaceticus, and Alcaligenes eutrophus (Reiner, 1971).
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Another enzyme which has been characterized from P. putida in addition to that
for 1,2-dihydro-1,2-dihydroxybenzoic acid is benzoylformate decarboxylase (BFD)
which catalyzes the decarboxylation of benzoylformate to benzaldehyde (Figure 13)
(Iding et al., 2000). Although seeming highly specific to the substrate benzoyl formate,
the decarboxylase showed minimal activity towards other carboxylic acid groups, in a pH
range viable for the human body (pH 7). Important to note is that the purified enzyme
did show stability at temperatures up to 60 °C for 2 hours.

Figure 13: Decarboxylation of benzoylformate to benzaldehyde.
In addition to the aforementioned body of literature, research conducted in our
laboratory supports the decarboxylation of cannabinoid model compounds (Cribbs,
2014). Three bacterial species, K. pneumonia, E. aerogenes, and P. putida displayed
decarboxylase activity for various substrates. P. putida was incubated with 2-hydroxy-4methoxybenzoic acid for one hour, after which time the presence of the decarboxylation
product, 3-methoxyphenol, was observed with intact cells. In contrast, incubation of E.
aerogenes in the presence of PHB produced the decarboxylation product, phenol, after 20
minutes with both intact and lysed cells. In this case, induction was not necessary prior
to incubation for decarboxylase activity; however, the amount of phenol produced was
less than when induced. Finally, K. pneumonia was observed to decarboxylate PHB to
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phenol following incubation for 30 minutes. After 60 minutes a marked decrease in PHB
and increase in phenol was shown (Cribbs, 2014).
Based on the reviewed literature and previous work by our research group, seven
cell lines were chosen for screening: Aspergillus niger, Aspergillus clavatus, Bacillus
subtilis, Enterobacter (Klebsiella) aerogenes, Klebsiella pneumonia, Penicillium
chrysogenum, and Pseudomonas putida. K. pneumonia, E. aerogenes, and P. putida
displayed decarboxylase activity for various model compounds in previous studies by our
research group and thus were carried forward to be screened with actual cannabinoids.
Bacillus subtilis has a well-characterized PAD enzyme which decarboxylates a variety of
compounds from Categories 1-4 and so was also chosen to be screened with
cannabinoids. The same rationale was used in choosing those cell lines from the
Aspergillus and Penicillum genera. The cells chosen contained decarboxylases which
covered a variety of structural variations from that of CBDA to have a more complete
understanding of which enzyme binding sites might be most compatible with the
structure of CBDA.
Cell-in-a-Box®
The Cell-in-a-Box® live cell encapsulation technology was developed by
Austranova, an Austrian biotechnology company, and employed by PharmaCyte Biotech
as a delivery system of cells which will potentially convert prodrugs to active drugs for
the treatment of a variety of different diseases. This delivery system is currently in
clinical trials for treatment of pancreatic and breast cancer, as well as diabetes.
PharmaCyte Biotech’s model for the treatment of cancer involves encapsulating
genetically-engineered human cells that convert an inactive chemotherapy drug into its
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active or “cancer-killing” form (PharmaCyte, 2017). Cells are encapsulated though a
reaction of two polymer coating steps in which the cells are mixed with one polymer and
then the mixture is introduced to the next polymer using a droplet-forming machine,
where the capsule membrane complex forms immediately around the droplets containing
cells, resulting in capsules with a diameter of 0.7-0.8 mm which can encapsulate as many
as 10,000 live cells (PharmaCyte, 2017).
The small, spherical capsules, made of a bio-inert cellulose-based polymer, are
designed to retain the engineered cells due to size, while preventing immunoglobulins
from entering the capsule and destroying the cells. The porous nature of the capsule
allows blood flow, which nourishes the living cells inside, and does not block circulation
when inserted into the blood stream. In cancer therapies, capsules are implanted as close
as possible to the patient’s cancerous tumor which can be done so safely by using needles
or catheters. Capsules that have been placed in the body for over two years have not
degraded nor caused damage or inflammation to the surrounding tissues (PharmaCyte,
2017).
Cell-in-a-Box® technology is currently being implemented in clinical trials for
the treatment of pancreatic cancer with the prodrug ifosfamide, a highly effective
chemotherapy drug. However, ifosfamide is typically given intravenously and activated
in the liver by cytochrome P450; consequently, the effective dose needed for the desired
anti-cancer effects of ifosfamide can cause serious side effects. With the use of Cell-in-aBox® technology, ifosfamide is given intravenously and converted to its active form
when it comes into contact with the encapsulated cells implanted in the blood supply near
the tumor instead of being converted in the liver and distributed throughout the body until
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reaching the tumor site. A pictorial schematic of this mechanism of action is presented in
Figure 14. In clinical trials, patients were able to receive a dose two-thirds less than the
usual, which decreased or completely eliminated the undesirable side effects.

Figure 14: General schematic of Cell-in-a-Box®/Ifosfamid technology.
In a phase 1 and 2 clinical trial, 14 patients were treated with the Cell-in-aBox®/Ifosfamide therapy. Cell-in-a-Box® capsules, with engineered cells which
expressed the P450 system like that of the liver where ifosfamid is usually metabolized,
were implanted on day zero. One dose of ifosfamide was given intravenously to patients
during the first week (days 2-5) and a second dose was given during the fourth week
(days 25-27), both at a dose of 1 g/m2. Individual results varied from 25-50% reduction
in tumor size; however, no patients showed tumor growth and two patients’ inoperable
tumors (due to size and location in the pancreas) became operable. These results were
compared with phase 3 historical data for gemcitabine, a pancreatic cancer treatment
currently approved by the FDA. The percentage of one-year survivors using the Cell-ina-Box® therapy was double that previously reported for patients using gemcitabine, the
median survival of patients was substantially increased as compared to gemcitabine, and
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in contrast to gemcitabine, no treatment-related side effects were seen with Cell-in-aBox®/Ifosfamid treatment (Pharmacyte, 2017).
In a phase 2 clinical trial using the Cell-in-a-Box®/Ifosfamid treatment, 13
pancreatic cancer patients were administered Cell-in-a-Box® technology in the same
manner as in the phase 1/2 trials, however a dose of 2 g/m 2 was given. The conclusion
was that a dose of 1 g/m2 was more appropriate, since that dose was able to effectively
treat the pancreatic tumors while still minimizing negative effects of the typical mode of
delivery for ifosfamid. A future trial, awaiting FDA approval, is designed to show that
Cell-in-a-Box® plus low-dose ifosfamide therapy can serve as an effective and safe
consolidation chemotherapy for patients whose tumors no longer respond after four to six
months of therapy with Abraxane® plus gemcitabine (PharmaCyte, 2017).
In addition to trials with human pancreatic cancer, a veterinary phase 1/2 trial
using dogs with breast cancer has been conducted. Cell-in-a-Box® capsules containing
cells with high CYP2B1 activity were used in combination with cyclophosphamide.
Because it is often used to treat breast cancer in humans as well as mammary tumors in
dogs, cyclophosphamide was chosen rather than ifosfamide. As in the pancreatic cancer
clinical trials in humans, the capsules showed no side effects or irritation at the implanted
sites (PharmaCyte, 2017).
A total of 16 dogs were enrolled in the preclinical trial. Ten dogs were treated
with the Cell-in-a-Box®/cyclophosphamide combination, one of which had two tumors.
Six of the 11 tumors from the dogs treated with the encapsulated cells/cyclophosphamide
combination showed a partial remission (PR, regression of initial tumor mass by less than
50%) while the other five tumors showed stable disease (SD, regression of the initial
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tumor mass by less than 50% or its enlargement by less than 25%). One group of six
dogs, one of which had two tumors, was treated intravenously with cyclophosphamide
alone at a dose of 7 mg/kg of body weight. Of the seven tumors in the six dogs that
received cyclophosphamide alone, six tumors showed SD and the other exhibited
progression of disease (PD, increase in initial tumor mass of at least 25% or the
occurrence of new tumors). The median tumor size reduction of the tumors in the ten
dogs treated with the combination Cell-in-a-Box®/cyclophosphamide was 53%. This is
in contrast with only a 21% reduction of the size of the tumors in the dogs treated with
cyclophosphamide alone (Michalowska et al., 2014). The results of this study suggest
that the combination of the Cell-in-a-Box®/cyclophosphamide treatment may prove to be
beneficial not only for the treatment of mammary cancers in the veterinary setting but
may also be translated into an effective treatment of breast cancer in humans. This
supports the application of the Cell-in-a-Box® technology as a treatment platform.
Summary
With the support from the studies reviewed in this chapter, this research aimed to
isolate the phytocannabinoid cannabidiolic acid from Cannabis sativa plant material and
to screen microbial cell lines which could potentially decarboxylate CBDA to CBD.
With the broad review of many different in vitro and in vivo studies citing the effects of
CBD on various cancer cell lines, this natural product clearly could be the basis of a
targeted cancer therapy. Cannabidiol is already an FDA-approved drug in other
medicinal contexts and its high potential for other therapies could be harnessed if an
appropriate manner of administration was developed. One approach involving Cell-in-aBox® begins with identifying a microbial cell line capable of enzymatic conversion of

38
the inactive prodrug cannabidiolic acid to cannabidiol by performing cell assays on a
variety of species from the literature discussed. Ultimately, Cell-in-a-Box® technology
could provide a potential mechanism of delivery for a genetically-engineered cell
containing the gene necessary for an enzyme capable of catalyzing the conversion of
prodrug to active drug.

39

CHAPTER III
METHODOLOGY
Chemicals and Reagents
Cannabidiolic acid (CBDA) (1244-58-2), cannabidiol (CBD) (13956-29-1), and
phytocannabinoid mixture 1 (18791) were obtained from Cayman Chemical Company
(Ann Arbor, Michigan). Chloroform-d (865-49-6) and formic acid (64-18-6) were
obtained from Acros Organics (Geel, Belgium). HPLC-grade acetonitrile (75-05-8),
absolute ethanol (64-17-5), n-pentane (109-66-0) and potassium hydroxide (1310-58-3)
were obtained from Fisher Scientific (Fair Lawn, New Jersey). Ammonium formate (54069-2), HPLC-grade methanol (67-56-1), ∆9-THC (1972-08-3) and salicylic acid (69-72-7)
were obtained from Sigma-Aldrich Chemical Company (St. Louis, MO). The sources for
the remaining chemicals and reagents are as follows: Tryptic soy broth (470015-844)
(BD Sparks, MD); sabouraud-dextrose broth (1466366) (EMD, Darmstadt, Germany).
Cannabis plant material (RTI log number 13784-1114-18-6, reference number SAF
027355, 6.5% CBD(A), 3.5% THC(A)) was obtained from the National Institute on Drug
Abuse. HPLC-grade water (18.2 MΩ) was purified in-house by passing reverse osmosis
purified water through a Milli-Q® Advantage A 10 Ultrapure Water Purification System.
Cells
Seven cell lines were screened for decarboxylase activity with CBDA.
Aspergillus clavatis (1007) and Apergillus niger (16888) were purchased from the
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American Type Culture Collection (Manassas, VA). Bacillus subtilis (470176-524),
Enterobacter (Klebsiella) aerogenes (470179-294), Klebsiella pneumoniae (470179122), Penicillium chrysogenum (470176-388) and Pseudomonas putida (470179-092)
were obtained from VWR International (Randor, PA) via Ward’s Science Co. (Rochester,
NY).
Preparation of Solutions
All mass measurements were made using an Ohaus Explorer Pro analytical
balance. The pH of buffer solutions was measured using a Fisher Scientific Accumet ®
AB150 pH meter. The meter was calibrated using buffers obtained from Fisher Scientific
at pH 4.0 (SB-101-500), 7.0 (SB-107-500), and 10.0 (SB-115-500). All solvents were
filtered prior to use with the HPLC. Aqueous solvents and methanol were filtered
through a nylon filter (0.22 μm) and all other organic solvents were filtered through a
Teflon filter (0.22 μm).
Ammonium formate (20.0 mM, pH 3.20) preparation. To prepare 1.00 L of
20.0 mM ammonium formate, 1.2612 g of ammonium formate were added to a 1000-mL
volumetric flask and diluting to volume with HPLC-grade water. Formic acid (20.0 mM)
was prepared by adding 0.3835 mL of 96% formic acid to a 500-mL volumetric flask and
diluted to volume with HPLC-grade water. The 20.0 mM formic acid solution was added
to the 20 mM ammonium formate solution until a pH of 3.20 was observed on the pH
meter.
Cannabidiolic acid (2.0 mg/mL) stock solution preparation. To prepare 700 µL,
1.4 mg of CBDA were added to a vial and dissolved in 700 µL of absolute ethanol, added
by a micropipette.
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Cannabidiol (2.0 mg/mL) stock solution preparation. To prepare 1.05 mL, 2.1 mg
of CBD were added to a vial and dissolved in 1.05 mL absolute ethanol, added by
micropipette.
Standard curve solutions for cannabidiolic acid. Five 200 μL standards with
concentrations of 0.10, 0.50, 1.0, 1.5, and 2.0 mg/mL were prepared by making
appropriate dilutions of the stock solution using a variety of Rainin Pipetman
micropipettes. The standards were diluted to a volume of 200 µL with absolute ethanol.
All standards were prepared in triplicate.
Standard curve solutions for cannabidiol. Five 200 μL standards with
concentrations of 0.10, 0.50, 1.0, 1.5, and 2.0 mg/mL were prepared by making
appropriate dilutions of the stock solution using a Rainin Pipetman micropipette. The
standards were diluted to a volume of 200 µL with absolute ethanol. All standards were
prepared in triplicate.
Induction solution preparation. The appropriate mass of the induction substrate,
according to assay, was dissolved in an appropriate solvent in a volumetric flask
depending on the substrate and the desired volume. For example, salicylic acid was
prepared as the potassium salt by dissolving the appropriate amount in an equimolar +
10% equivalent of KOH in a 250-mL volumetric flask. An additional 25 mL of absolute
ethanol were added then diluted to volume with HPLC-grade water.
Construction of Calibration Curves
Calibration curves for both CBDA and CBD were constructed for use to
determine the concentration of both CBDA present and CBD formed, if any, from the
signal produced during HPLC analysis. A 2.0 mg/mL stock solution of each compound
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was prepared and then diluted with absolute ethanol to make solutions of 1.5, 1.0, 0.50,
and 0.10 mg/mL. Each standard was prepared in triplicate and analyzed using the
analytical HPLC method. The area under the curve of the analyte peak was averaged
across the triplicate solutions and plotted in Microsoft Excel against concentrations to
generate a standard curve.
Isolation of Cannabidiolic Acid
from Cannabis Plant Material
Initially, 5.00 g of Cannabis plant material, containing a reported 6.5% CBD(A)
content, obtained from the National Institute for Drug Abuse was freeze-dried and
pulverized with a mortar and pestle prior to extraction. The dry material was placed in a
filter paper thimble which was then placed into the main chamber of a Soxhlet extractor.
The Soxhlet extractor was placed onto a round-bottom flask containing 100 mL of
pentane which was then heated to a gentle reflux in a continuous solid-liquid extraction
for three hours. After extraction, the pentane was removed by rotary evaporation to
recover a dark green-brown, oily and viscous extract containing CBDA and other
cannabinoids. The resulting oil was resuspended in 15 mL ethanol and gravity filtered to
remove any insoluble solids. CBDA was isolated from the resulting solution as described
in the Preparative Method for Purifying CBDA from a Crude Cannabis Extract outlined
in the Instrumentation section of Methodology.
Cell Culture
Cells were cultured in 500-700 mL of appropriate growth medium and incubated
at room temperature or 37 °C according to species. Cells were induced for 24-72 hours
with model compounds known for inducing decarboxylase activity. Treatments for each
assay are listed in Table 9 (Appendix A). For example, salicylic acid was added to a
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culture of Pseudomonas putida to give a final concentration of 1 mM and incubated for
72 hours to induce expression of decarboxylase enzymes. Following induction, cells were
centrifuged in 50-mL conical tubes at 4000g for 10 minutes to collect all cells in a pellet.
Wet cell mass of the final cell pellet was obtained in mg/mL. Cells were resuspended in
30 mL of fresh culture medium and divided between two 50-mL conical tubes. One
sample was sonicated to lyse the cells or used intact for assessing decarboxylase activity.
Sonication was performed using a Branson Digital sonifier using a program designed to
sonicate the sample at 40% amplification using one second bursts followed by a one
second pause for a total of twenty seconds. Cells were on ice during sonication to ensure
that the sample remained cool. The other sample, used as control, was autoclaved. All
samples were kept on ice until screened for enzymatic activity.
Cell Assay for Decarboxylase Activity
Each strain of microbial cells was grown according to the procedure outlined in
the Cell Culture section of Methodology. Cells were assessed for enzymatic
decarboxylation of CBDA alongside an autoclaved control. Cells were assayed at a range
of concentrations of CBDA from 0.23-0.36 mM by making solutions of 1.1-1.75 mg of
CBDA in 100 µL of absolute ethanol and adding to the incubation medium. Specific
concentrations of CBDA are given in Table 9 (Appendix A). Addition of the CBDA
solution (100 µL) to the incubation flask was followed by the addition of 15.0 mL of cell
suspension. The solutions were incubated in a constant-temperature, shaking water bath
from VWR International at 36 °C and shaken at 60 rpm for the duration of the assay.
Incubation media was removed in 2.0 mL aliquots at time = 0, 1, 2, 3, 4, 5, and 6 hours
and immediately extracted with 5.0 mL of pentane containing 0.5 mL absolute ethanol by
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vortexing with the 2.0 mL aliquot of incubated media. The cannabinoid-containing
pentane layer was separated from the cell suspension using centrifugation; the pentane
layer was transferred into a separate vial and evaporated to dryness using nitrogen gas.
The residue was resuspended in 100 µL of absolute ethanol. A 20 µL aliquot of the
ethanol solution was loaded into the HPLC 10 µL loop injector and analyzed for the
presence of CBD using HPLC in accordance to the Analytical Method for Monitoring
Conversion of CBDA to CBD outlined in the Instrumentation section of Methodology.
Instrumentation
Analytical High Performance Liquid
Chromatographic Method for
Monitoring Conversion of
Cannabidiolic Acid to
Cannabidiol
HPLC analyses were performed using a Shimadzu (Tokyo, Japan) VP equipped
with a SPD-M10A diode array detector, a Shimadzu SCL-10A system controller, with a
DGU-14A degasser, one LC-10AT pump, and a FCV-10AL Low Pressure Valve
Module. Injection was through a 10 μL injection loop. Separations were obtained on a
reverse phase analytical column (Luna Omega 5 μm Polar C18 100 LC column 150 × 4.6
mm with a 4.0 × 3.0 mm guard column) obtained from Phenomenex which was housed in
a Shimadzu CTO-10AS column oven set to 30 °C.
A 20 minute long, two-solvent gradient method was used with 20 mM ammonium
formate buffer, pH 3.20 (solvent A) and HPLC-grade acetonitrile (solvent B). The
gradient steps began with 60% solvent B increased to 95% solvent B over a nine-minute
period, held at 95% for three minutes and then reduced back to 60% solvent B by minute
sixteen and held at 60% until the end of the run. Flow rate was maintained at
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1.2 mL min-1. The diode array detector was set to scan in 1 nm increments from
190 – 800 nm.
CBDA and CBD were identified by comparing their retention times to those of
reference standards. Under these conditions, the retention times of CBDA and CBD were
7.0 and 8.1 minutes, respectively. Chromatograms were generated with CLASS-VP 7.2.1
SP1 software.
Preparative High Performance Liquid
Chromatographic Method for
Purifying Cannabidiolic
Acid from a Crude
Cannabis Extract
A Shimadzu VP HPLC was used to develop a preparative method for purifying
CBDA from a crude Cannabis extract. The HPLC was equipped with a CBM-10AW
communications bus module and a SPD-10A UV-VIS detector DGU-14A degasser, two
LC-10AT pumps, and a 1.00 mL injection loop. Separations were obtained on a
preparative reverse phase column (Luna Omega 5 μm Polar C18 100 LC column
150×21.2 mm with a Polar C18 SecurityGuard prep cartridge, 15×21.2 mm) obtained
from Phenomenex, housed in a Shimadzu CTO-10A column oven set to 30 °C. A Gilson
FC-100 microfractionator was connected to the HPLC effluent outlet and used to collect
the separated compounds.
A 90 minute long, two-solvent gradient method was used with 20 mM ammonium
formate buffer at 3.20 pH (solvent A) and HPLC-grade acetonitrile (solvent B). The
gradient steps began with 50% solvent B held for five minutes and increased to 95%
solvent B over a 55-minute period, 95% solvent B was maintained for 10 minutes, and
then decreased back to 50% over the remaining 20-minute period. Flow rate was
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maintained at 4.5 mL min-1. The two channels of the UV-VIS detector were set to 220
nm and 274 nm. Under these conditions, the retention time of CBDA on the preparatory
column was found to be 46 minutes. Chromatograms were generated with CLASS-VP
7.2.1 SP1 software.
CBDA was identified by collecting major peaks using the Gilson FC-100
microfractionator set to collect in one-minute increments beginning 40 minutes into the
run. The test tubes containing the major peaks were collected from the fractionator. Test
tubes which contained fractions of the same peak were combined. Each sample
representing a peak in the chromatogram was placed into a 50-mL round-bottom flask.
Cannabinoids were recovered from the HPLC solvent solution by first rotary evaporating
the acetonitrile and then back extracting the cannabinoids from the remaining ammonium
formate solution into 5.0 mL pentane. The pentane layer was transferred with a Pasteur
pipette to a test tube. The pentane was evaporated to dryness using nitrogen gas and the
resulting residue was resuspended in 1.0 mL ethanol.
Infrared Spectroscopy Procedure
A Thermo Scientific Nicolet iS5 IR equipped with an iD5 ATR accessory and
zinc selenide crystal was used to acquire IR spectra using the OMNIC software. A
1.0 mg sample of CBDA recovered from the preparative HPLC was applied to the
surface of the crystal. After the pressure arm was lowered and secured, the sample was
analyzed. Obtained spectra were compared to standard spectra from a study by
Hazekamp, Peltenburg, Verpoorte & Giroud (2005).
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1H-

and 13C Nuclear Magnetic
Resonance Procedure
A Bruker 400 MHz NMR was used with TOPSPIN 1.3 software program to
generate all NMR spectra. Confirmatory 1H- and 13C-NMR spectra were acquired for
cannabidiolic acid isolated using the outlined preparative HPLC method. Since the
recovered CBDA was initially dissolved in 1.0 mL ethanol, the sample was evaporated to
dryness with nitrogen gas and the residue (3.7 mg) was resuspended in 600 μL of
deuterated chloroform for NMR analysis. Obtained spectra were compared to standard
spectra of cannabinoids from a study by Choi et al. (2004).
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CHAPTER IV
RESULTS AND DISCUSSION
This study had a dual purpose, to isolate CBDA from the plant Cannabis sativa
and to identify a microbial cell line which possesses a decarboxylase enzyme capable of
converting CBDA to CBD. Before various cells could be screened for decarboxylase
activity, the optimal conditions for the chromatographic column and mobile phase had to
be confirmed to ensure optimal separation and identification of the cannabinoids. This
analytical method was employed to monitor any enzymatic conversion of CBDA to CBD
in the enzymatic assays and as a confirmatory method for preparatory isolation of CBDA.
Once developed, cell lines could be monitored for CBDA decarboxylase activity. The
following sections discuss results from HPLC methodology development, CBDA
isolation, and enzymatic assays.
Analytical Method for Monitoring
Conversion of Cannabidiolic Acid
to Cannabidiol
Model compounds from previous studies were separated by HPLC on a Tosohaus
C18 column using an isocratic method consisting of 35% methanol and 65% 0.5 M
potassium acetate buffer, pH 3.0, with a flow rate of 1.0 mL/min at room-temperature
(Cribbs, 2014); however, this method was not suitable since it was not able to baseline
resolve CBDA and CBD well. Separating these two coumpounds was particularly
challenging because there is such a small difference in the chemical formula, molecular

49
weight, and the physical and chemical properties of CBDA and CBD. The reverse phase
polar C18 (Luna Omega 5 µm Polar C18 100 Å, LC Column 150 x 4.6 mm) column was
obtained from Phenomenex who suggested an isocratic mobile phase of 25% water +
0.1% formic acid and 75% acetonitrile + 0.1% formic acid reported in their applications.
They also reported a fifteen minute-long gradient method using 20 mM ammonium
formate, pH 3.2 (solvent A) and acetonitrile (solvent B) for a similar column with
different dimensions (Luna Omega 1.6 µm C18 100 Å, LC Column 100 x 2.1 mm). This
method began by increasing solvent B from 60% to 95% over 12 minutes, holding for
one minute, and then decreasing solvent B back to 60% during the remaining time at a
flow rate of 0.4 mL min-1 at 40 °C. The gradient approach was taken; however results
reported by Phenomenex® could not be replicated with the difference in columns. The
initial concentration of solvent B was increased from 5% to 60%, flow rate was increased
to 1.2 mL min-1, and column temperature was decreased to 30 °C. This achieved greater
separation of various cannabinoids. The optimized analytical method is described under
the Instrumentation section in Chapter III (Methods).
With the optimized analytical HPLC method, standards of CBDA and CBD were
analyzed to confirm the identity of analyte peaks from enzymatic assays and CBDA
isolation by matching their retention times with that of these standards. The retention
times of CBDA and CBD were determined to be 7.0 min (Figure 15) and 8.3 min (Figure
16), respectively. Baseline separation of both compounds was achieved (Figure 17)
which allows for the conversion of CBDA to CBD to be monitored. Interesting to note is
the difference in retention times of CBDA and CBD when in a mixture than when pure,
possibly due to intermolecular interactions such as hydrogen bonding. Cannabidiolic
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acid had a retention time of 7.0 min. when pure in an ethanolic solution compared to 7.5
min in an ethanolic solution with CBD. Cannabidiol's retention time in a mixture with
CBDA was shifted to 8.3 min from 8.1 min when analyzed with this method.

Figure 15: Chromatogram of 2.0 mg/mL CBDA standard using the analytical HPLC
method. Retention time 7.0 minutes.

Figure 16: Chromatogram of 2.0 mg/mL CBD standard using the analytical HPLC
method. Retention time 8.1 minutes.
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Figure 17: Chromatogram of a mixture of 1.0 mg/mL CBDA and 1.0 mg/CBD using the
analytical HPLC method. CBDA retention time 7.5 min, CBD retention time 8.3 min.
Standard curves for both CBDA (Figure 18) and CBD (Figure 19) were
constructed to quantify any enzymatic conversion during cell assays based qualitatively
on the appearance of the CBD peak. Solutions of CBDA and CBD were prepared in
triplicate over a range of concentrations (0.10 – 2.0 mg/mL) and analyzed using the
analytical HPLC method. The area under the curve for each run of the same
concentration was averaged and plotted against the concentration. Areas and averages
for peaks from various concentrations of CBDA and CBD standards are given in Table 1
and Table 2, respectively.
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Table 1: Area of Cannabidiolic Acid Peak at Different Concentrations Using the
Analytical HPLC Method.
CBDA
Concentration
Standard
(mg/mL)
Trail 1
Trial 2
Trial 3
Average
Deviation
2.0
4.07 x 107 3.90 x 107
4.00 x 107
3.99 x 107
6.96 x 105
1.5

2.92 x 107

3.46 x 107

3.11 x 107

3.16 x 107

2.27 x 106

1.0

2.48 x 107

2.26 x 107

2.08 x 107

2.27 x 107

1.64 x 106

0.5

9.26 x 106

8.30 x 106

8.22 x 106

8.59 x 106

4.72 x 105

0.1

4.72 x 106

1.06 x 106

5.36 x 106

3.71 x 106

1.89 x 106

2.0

2.5

4.50E+07
4.00E+07
3.50E+07

y = 2E+07x + 997385
R² = 0.9884

Peak Area

3.00E+07
2.50E+07
2.00E+07
1.50E+07
1.00E+07
5.00E+06
0.00E+00
0.0

0.5

1.0

1.5

CBDA Concentration, mg/mL
Figure 18 : Standard calibration curve for cannabidiolic acid.
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Table 2: Area of Cannabidiol Peak at Different Concentrations Using the Analytical
HPLC Method.
CBD
Concentration
(mg/mL)
2.0

Trial 1
2.40 x 107

Trial 2
2.48 x 107

Trial 3
2.38 x 107

Average
2.42 x 107

Standard
Deviation
4.56 x 105

1.5

1.87 x 107

1.87 x 107

1.93 x 107

1.89 x 107

2.42 x 105

1.0

1.70 x 107

1.67 x 107

1.52 x 107

1.63 x 107

7.79 x 105

0.5

7.94 x 106

8.07 x 106

8.02 x 106

8.01 x 106

5.29 x 104

0.1

2.05 x 106

2.15 x 106

1.94 x 106

2.05 x 106

8.57 x 104

3.00E+07

Peak Area

2.50E+07

y = 1E+07x + 2E+06
R² = 0.969

2.00E+07
1.50E+07
1.00E+07
5.00E+06
0.00E+00
0.0

0.5

1.0

1.5

CBD Concentration, mg/mL
Figure 19: Standard calibration curve for cannabidiol.
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Isolation and Characterization
of Cannabidiolic Acid
Preparative High Performance Liquid
Chromatographic Method for
Purifying Cannabidiolic Acid
from a Crude Cannabis
Extract
In addition to the analytical HPLC method, a preparatory HPLC method for
cannabinoids was developed for the purpose of isolating pure CBDA from the crude
Soxhlet Cannabis extract. Crude extract was prepared from 5.00 g of Cannabis
containing a reported 6.5% CBDA (0.325 g) as outlined in Methodology. The extract
was initially analyzed on the preparatory column using a two-solvent gradient, referred to
as Gradient 1 (Figure 20), at 30 °C, with a flow rate maintained at 5 mL min -1, however
poor separation was achieved (Figure 21). The length of the gradient step from 25% to
95% acetonitrile was increased from 65 minutes to 95 minutes, while flow rate was
decreased to 4.5 mL min-1 to make Gradient 2 (Figure 22). This method was able to
achieve separation of at least 4 major components (Figure 23).
Because the first compounds from the extract eluted one hour into the run,
analysis time was shortened by 60 minutes by increasing the starting percentage of the
eluent from 25% to 50% acetonitrile. The temperature and flow rate from Gradient 2 was
maintained. The resulting method (Gradient 3, Figure 24) was able to resolve
cannabinoids (Figure 25) in a similar manner to Gradient 2 in 30 minutes less and with
32.5% less solvent than the originally suggested method using Gradient 1. Both time and
materials can be costly so optimizing the method in this way was ideal to save valuable
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resources with very simple adjustments. The optimized preparatory method is described
under “Instrumentation” in Chapter III (Methods).
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Figure 20: Gradient Method 1

Figure 21: Chromatogram of CBDA extract from Soxhlet extraction using the
preparatory HPLC method with Gradient 1.
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Figure 22: Gradient Method 2

Figure 23: Chromatogram of CBDA extract from Soxhlet extraction using the
preparatory HPLC method with Gradient 2.
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Figure 24: Gradient Method 3

Figure 25: Chromatogram of CBDA extract the from Soxhlet extraction using the
preparatory HPLC method with Gradient 3.
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When the sample concentration exceeds the range of the detector, the detector
cannot generate a larger response, and typically a flat-topped peak is observed, referred to
as detector overload (Dolan, 2015). Two flat-topped peaks in the chromatogram were
observed, so to address this issue the extract was diluted with two successive 1:2
dilutions with absolute ethanol prior to injection on the HPLC which was sufficiently
dilute to prevent detector overload (Figure 26). This dilution factor also allowed for only
the seven most abundant cannabinoids to be detected.

Figure 26: Chromatogram of CBDA extract, after two successive 1:2 dilutions with
absolute ethanol from the Soxhlet extraction using Gradient 3.
Chromatographic Characterization
of Cannabidiolic Acid
Once the preparative HPLC method was optimized, fractions were collected every
minute to isolate each individual peak for analysis. Thirty test tubes of 4.5 mL of eluent
were collected in total. Of the thirty, nine test tubes contained compounds of interest
which corresponded to seven peaks on the chromatogram and these were collected for

59
analysis. A summary of fractions collected is given in Table 3. Fractions were prepared
for analysis by combining test tubes which contained eluent from the same peak. The
acetonitrile was removed by rotary evaporation and the cannabinoids were extracted from
the remaining ammonium formate solution with 5 mL of pentane. The pentane was then
evaporated to dryness with nitrogen gas; the resulting residue was resuspended in 1.0 mL
absolute ethanol and analyzed by the analytical HPLC method.
Table 3: Summary of Collected Fractions from the Preparatory HPLC Method.
Collection
Time
40-44
45-46
47
48-49
50
51
52
53-55
56
57-58
59
60-61
62-70

Fraction
Number
1-5
6-7
8
9-10
11
12
13
14-16
17
18, 19
20
21, 22
23-30

Peak Number
(Figure 26)
N/A
1
2
N/A
3
N/A
4
N/A
5
N/A
6
7
N/A

Peak Area
251815642
53227248
75508734
16942665
17919678
17791656
294579036
-

Retention
Time (min.)
46.025
47.683
50.492
52.300
56.700
59.233
60.758
-

Identity
CBDA
Unknown
Unknown
Unknown
Unknown
Unknown
THCA
-

The most abundant cannabinoids of Cannabis sativa are ∆9-THCA and CBDA
(Elsohly & Slade, 2005). The area under the curve of peak 1 and peak 7 accounted for
more than 55% of all compounds detected, making up 29.92% and 25.58 % of the area,
respectively as reported in the generated area report. Because peak 1 and 7 (Figure 26)
were the most abundant, this suggested that the identity of the compounds which
produced these peaks may be CBDA, the analyte of interest, and ∆9-THCA, the other
most abundant cannabinoid in the extracted Cannabis sample. The compound from the
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first major peak, collected from fractions 6 and 7, had a retention time of 46.025 minutes
using the preparatory HPLC method. When analyzed with the analytical HPLC method,
the compound had a retention time of 7.0 minutes (Figure 27) which matched the
retention time for the standard CBDA (Figure 28). This was the first indication that
CBDA had been successfully recovered from the Soxhlet extraction of the Cannabis
plant material followed by the preparatory HPLC method. The identity of the compound
which produced peak 1 (Figure 26) as CBDA was further supported by NMR and IR
spectroscopy.

Figure 27: Chromatogram using the analytical HPLC method of the compound recovered
from peak 1. Retention time 7.0 minutes.

Figure 28: CBDA standard (2.0 mg/mL) using the analytical HPLC method. Retention
time 7.0 minutes.
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Nuclear Magnetic Resonance
Spectral Analysis
Both 1H-NMR and 13C-NMR spectra of the compound from peak 1 were obtained
for comparison to spectra reported in the literature by Choi et al. (2004) and by
Hazekamp, Choi and Verpoorte (2004). The study by Choi et al. (2004), which studied
∆9-THCA, THC, ∆8-THC, CBG, CBN, CBDA, CBD, and two flavonoids, was used for
overall assignment of each peak in the 1H-NMR and 13C-NMR spectra. Unique singlets in
the range of 𝛿 4.0—7.0 in the 1H-NMR spectrum of ∆9-THCA, THC, CBDA, CBD, and
CBN reported by Hazekamp et al., were used to further support the identity of CBDA
once the spectrum was fully assigned. The numbering scheme for cannabidiolic acid used
in these two studies is given in Figure 29. Although the spectra for cannabidiolic acid
from the Choi et al. study were not provided, they reported a table of chemical shifts
(ppm) with reference to TMS. Table 7 compares actual values from the 1H- and 13CNMR obtained for the compound in peak 1 with values reported in the Choi et al. study
for cannabidiolic acid.
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Figure 29: Numbering scheme used by Choi et al. (2004) for CBDA.
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Table 4: Comparison of 1H- and 13C-NMR Spectra of the Compound Isolated from Peak 1 to
Assignments for Cannabidiolic Acid Reported by Choi et al. (2004).
1
13
H NMR
C NMR
ppm
ppm
Position (actual, peak 1)
(literature)
ppm (actual)
1
4.09
4.09
35.36
2
5.57
5.56
123.84
3
140.55
4
2.23
2.2
30.17
5
*
1.86
27.7
6
2.38
2.4
46.6
7
1.8
1.8
23.7
8
147.8
9
4.54
4.55
111.34
4.39
4.4
10
1.72
1.72
1'
18.86
2'
114.45
3'
164.1
4'
102.5
5'
6.26
6.26
147.1
6'
111.9
1''
2.92, 2.82
2.92, 2.82
161
2''
1.58
1.57
36.56
3''
1.33
1.33
31.2
4''
1.33
1.33
31.97
5''
0.89
0.89
22.54
2'-OH
11.85
11.93
14.07
6'-OH
6.65
6.63
COOH
176.06
*peak is absent in the spectra, assumed to be buried beneath the signal at 1.8 ppm

ppm
(literature)
37.3
126.9
133
31.7
30.8
45.7
23.6
150.4
110.5
19.3
116.5
161.8
104.2
147
111.3
150.4
37.6
32.8
33.2
23.5
14.4
175.6

In the 13C-NMR spectrum of the isolated compound (Figure 30), twenty-two
distinct carbon peaks were observed as would be expected for cannabidiolic acid
(C22H30O4) (Figure 29). Choi et al. reported only twenty-one distinct peaks, noting that
carbons in position 8 and 6’ overlapped and appear as one signal at 150.4 ppm.
Differences in chemical shifts from those reported in the literature could be attributed to
the fact that Choi et al. obtained 13C NMR spectra at 100 MHz in deuterated methanol,
whereas the spectra obtained in this study were obtained at 100 MHz in deuterated
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chloroform making it possible for the electronic environment of the atoms in these
solutions to be different due to solute-solvent interactions.

Figure 30: 13C-NMR spectrum of the compound isolated from peak 1 in CDCl 3.
Unlike the 13C-NMR, conditions for obtaining 1H-NMR spectra were the same in
both the literature references and in this study. As shown in Figure 31, a carboxylic acid
proton is observed at 11.858 ppm, as would be expected from a carboxylic acid proton.
Choi et al. reported the proton signal at 11.93 is from the 6’ -OH but did not report a
carboxylic acid hydrogen which typically is observed between 10-13 ppm. Phenolic
hydrogens with intramolecular hydrogen bonding have a much broader range (10.5-16
ppm) (Jackman and Sternhell, 1969), thus it is possible that the signal is indeed from the
6’-OH and that the carboxylic acid hydrogen is absent. A carboxylic acid carbon signal
can be observed, however, in the 13C spectrum at 176 ppm, thus it can be confirmed that
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the carboxylic acid carbon is present. The H-5 signal was not observed in the spectrum
for the compound from peak 1, however the H-7 peak at 1.80 ppm integrated for six
hydrogens when it should integrate for three hydrogens. The H-5 signal that is supposed
to be present at 1.86 ppm could be buried beneath this peak, accounting for two
hydrogens, suggesting that the last hydrogen which was unaccounted for in the
integration to be the 6’-OH hydrogen.

Figure 31: 1H-NMR spectrum of compound isolated from peak 1 in CDCl 3
Because the disputed signals are from acidic hydrogens in CBDA, a technique for
confirming signals from exchangeable protons called a deuterium exchange was
performed by adding 100 µL of D2O directly into the NMR tube containing the sample.
Spectra of the CBDA isolated from the preparatory column before (A) and after (B) the
addition of D2O are presented in Figure 32. The absence of the signals at 11.85 and 6.65
ppm in the spectrum after deuterium exchange (Fig. 32 B) confirms that those two signals
came from exchangeable hydrogens. No additional information was gained as to the
assignments of the carboxylic acid -OH, 6’-OH, and 2’-OH. In order to further validate
that the compound was in fact CBDA, signals in the 4.0-7.0 region where distinguishable
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singlets between cannabinoids can be observed were compared. Four distinct signals for
H-4, H-10, H-9 trans and H-10 cis are reported at 6.26, 5.55, 4.54, and 4.40 in the
literature (Hazekamp et al., 2004) and observed in the spectrum obtained.

Figure 32: Deuterium exchange experiment for the compound isolated from peak 1. (A)
before the addition of D2O and (B) after the addition of D2O.
Infared Spectral Analysis
Additional spectral analysis included infrared spectroscopy which was obtained
from a viscous 1.0 mg sample of the compound isolated from peak 1. A broad peak in
the IR spectrum, starting at approximately 3400 cm -1, can be observed (Figure 33) as well
as a sharp peak at 1617.30 cm-1 and a sharp peak at 1257. 32 cm-1. These three signals
together are indicative of a carboxylic acid -OH and its C=O and C-O stretches.
Comparing this spectrum to the IR spectrum by Hazekamp et al. (2005), both have a
broad carboxylic acid peak, along with sharp peaks at approximately 1250 cm -1. The
peaks protruding around 2900 cm-1 match C-H stretched indicated by Hazekamp et al.
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This spectrum provided further confirmation that the identity of the compound present in
peak 1 is CBDA.

Figure 33: IR analysis of the compound isolated from peak 1.
Recovery
The Cannabis plant material contained a reported 6.5% CBDA. To determine the
perecnt of CBDA recovered by preparatory HPLC following Soxhlet extraction, a
0.5 mL sample of pure extract was separated by preparatory HPLC, collected by the
fractionator, and processed with rotary evaporation and back-extraction into pentane.
The pentane was evaporated in a pre-weighed container and the mass of the recovered
CBDA was detemined for the 0.5 mL injection volume. This mass was multiplied by 32
to account for the total volume of 16 mL for the extract. On average, 77.4 % of the
repored CBDA was recovered from the 0.325 g expected from 5.00 g plant material .
Table 5 summarizes recovery data.
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Table 5: Percent Recovery Data
Calculated total
Injection
CBDA Recovered* (g)
CBDA extracted (g)
1
0.00755
0.2416
2
0.00841
0.2691
3
0.00697
0.2440
*Recovered from 0.5 mL injection of pure extract

% CBDA
Recovered
74.34
82.81
75.08

Other Cannabinoid Analyses
Although CBDA was the focus of this study, this preparatory method could
potentially be used to separate a variety of compounds extracted from Cannabis plant
material. The compound from the last major peak, peak 7, collected from fractions 21
and 22, had a retention time of 60.8 minutes on the preparatory column. When analyzed
with the analytical HPLC method, the compound had a retention time of 10.8 minutes
(Figure 34) which was comparable with a reference standard for THCA with a retention
time of 10.6 min (Figure 35). When THCA is in a mixture of cannabinoids, it appears to
elute slightly later than when in an pure solution, similar to the effect observed when
CBDA and CBD are in a mixture.

Figure 34: Chromatogram using the analytical HPLC method of the compound recovered
from peak 7 using the preparatory HPLC method. Retention time 10.8 minutes.
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Figure 35: Chromatogram of THCA standard (1.0 mg/mL). Retention time 10.6 minutes
.
In an effort to identify which other cannabinoids were present, an additonal
preparatory run was performed but instead of collecting individual fractions all
compounds which eluted between 40 and 70 minutes were collected. This fraction was
prepared for analysis and chromatographed on the analytical column (Figure 36), which
was compared to the phytocannabinoid standard mixture (Figure 37) that contained 100
μg/mL of each of the following cannabinoids: CBDA, cannabigerolic acid (CBGA),
cannabigerol (CBG), CBD, tetrahydrocannabivarin (THCV), cannabinol (CBN),
∆9-tetrahydrocannabinolic acid (∆9-THCA), ∆9-tetrahydrocannabinol (∆9-THC), ∆8tetrahydrocannabinol (∆8-THC), and cannabichromene (CBC).

Figure 36: Chromatogram generated using the analytical HPLC method of the
cannabinoid mixture recovered from the 40-70 minute fraction using the preparatory
HPLC method with Gradient 3.
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Figure 37: Chromatogram of phytocannabinoid mixture standard using the analytical
HPLC method.
It appears that, like CBDA and CBD, other cannabinoids will elute at different
times in a mixture possibly due to interactions between compounds than when in a pure
sample. It was assumed that the peak at 7.9 minutes (Figure 36) is CBDA and the peak at
11.3 minutes is THCA due to abundance and order of elution. It appears that the crude
extract contains several of the standard cannabinoids: one which elutes at 8.4 min., the
next at 8.9 min., followed by one at 9.6 min. and one which elutes at 10.1 min. Each
fraction was analyzed with the analytical HPLC method and chromatograms were
collected (Appendix B). These chromatograms indicated that each sample was impure
and therefore not suitable for further analysis to confirm the identity. If pure cannabinoid
standards were obtained, other than the major cannabinoids, more studies could follow to
identify which of the standards match the compounds in this crude extract; however, this
was outside the scope of this study.
Cell Assay for Decarboxylase Activity
To identify a microbial species which exhibits decarboxylase activity, seven cell
lines were screened, four bacterial and three fungal. Species were chosen based upon
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literature reports of decarboxylase activity for compounds similar in structure to CBDA.
Species were screened using cells which were either intact or lysed and either induced or
uninduced depending on the assay. A summary of cell assays is given in Table 6. A full
description of the various combinations of conditions for each assay is given in Table 7
(Appendix A).
Table 6: Summary of Cell Incubations for Decarboxylase Activity.
Cell Type
Aspergillus niger

Intact
No

Lysed
Yes

Induced
Yes

Induction Substrate
Salicylic acid

Aspergillus clavatus

No

Yes

Yes

Salicylic acid

Bacillus subtilis

Yes

Yes

Yes

Salicylic acid or
4-hydroxybenzoic acid

Enterobacter
(Klebsiella) aerogenes

Yes

Yes

No

Not induced

Klebsiella pneumonia

Yes

Yes

Yes

2,4-dihydroxybenzoic acid

Penicillium
chrysogenum

No

Yes

Yes

Salicylic acid

Pseudomonas putida

Yes

Yes

Yes

Salicylic acid or
2,4-dihydroxybenzoic acid

From the bacteria screened, B. subtilis, E. aerogenes, and K. pneumonia displayed
no detectable CBDA decarboxylase activity; representative chromatograms for each
species are given in Appendix C1, C2, and C3, respectively. B. subtilis was assayed
under various combinations of intact/lysed and uninduced/induced conditions, however
no CBDA decarboxylase activity was observed. This cell line was not tested with model
compounds but was chosen because it expresses the genes for both a phenolic acid
decarboxylase and a phenylacrylic acid decarboxylase. Duy et al. (2007) showed that
these enzymes were both expressed when induced with salicylic acid. However, even
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after induction with salicylic acid no CBDA decarboxylase activity was observed in the
current study when B. subtilis was incubated in the presence of CBDA.
E. aerogenes contains an enzyme which decarboxylates both Category 1 and 2
substrates, and this cell line was assayed both intact and lysed. Earlier work by Cribbs
(2014) demonstrated the ability of lysed E. aerogenes cells to decarboxylate the Category
2 substrate p-hydroxybenzoic acid but not any phenolic carboxylic acid with hydroxyl
groups ortho to the carboxylic acid. A permeability barrier for the substrate of the
decarboxylase was noted in the study by Grant and Patel (1969) which could explain the
lack of activity in intact cells. An optimal pH of 6 was also noted which could explain a
lack of detectable activity when incubated in the presence of CBDA, even with lysed
cells, because all assays were performed at the pH of the media.
Both intact and lysed K. pneumonia cells, induced with 2,4-dihydroxybenzoic
acid, were incubated in the presence of CBDA. No decarboxylase activity was observed
in any of the three assays performed. Like E. aerogenes, the decarboxylase enzyme from
K. pneumonia is able to decarboxylate the Category 2 substrate p-hydroxybenzoic but no
model compound with a phenolic hydroxyl group ortho to the carboxylic acid (Cribbs,
2014).
None of the fungal species screened displayed CBDA decarboxylase activity
when incubated in the presence of CBDA. Representative chromatograms for assays of
A. clavatus, A. niger, and P. chrysogenum are given in Appendix C4, C5, and C6,
respectively. Aspergillus clavatus was not tested with model compounds but was chosen
because it has the patG gene, which codes for an enzyme that decarboxylates 6methylsalicylic acid. Two assays of Aspergillus clavatus induced with salicylic acid and
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one assay of A. clavatus induced with CBDA were performed but no CBDA
decarboxylase activity was observed. Penicillium chrysogenum and Aspergillus niger did
not demonstrate any decarboxylase activity when incubated with model compounds
(Cribbs, 2014) or with CBDA in the current study.
In previous studies, Pseudomonas putida was demonstrated to catalyze the
decarboxylation of 2-hydroxy-4-methoxybenzoic acid (Cribbs, 2014). In the current
study, twelve assays were performed for CBDA decarboxylase activity with P. putida. A
representative set of chromatograms are presented in Figures 38-42. Individual
treatments for each assay are given in Table 7, (Appendix A) and additional
representative chromatograms are given in Appendix C7. CBDA typically elutes at 7.0
minutes with the analytical HPLC method; however the column oven was not set, and
samples were run at ambient room temperature for this assay, resulting in retention times
of the standards for CBDA and CBD 7.8 and 8.3 minutes, respectively. Figure 38 shows
a chromatogram of an incubation extraction at time 0 with only one major peak, CBDA at
7.8 minutes. After 1 hour, CBDA was still the only species present (Figure 39). After 2
hours of incubation, the peak for CBDA was still be observed, and a peak for CBD
appeared at 8.3 minutes (Figure 40). The observation of both peaks persists at time 3 hr.
(Figure 41) and 4 hr. (Figure 42), with a slight increase in peak intensity in the final hour,
t = 4 hr., of assay.
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Figure 38: Chromatogram of CBDA after 0 hours of incubation with lysed P. putida.
CBDA is observed at 7.8 min.

Figure 39: Chromatogram of CBDA after 1 hour of incubation with lysed P. putida.
CBDA is observed at 7.8 min.

Figure 40: Chromatogram of CBDA after 2 hours of incubation with lysed P. putida.
CBDA (7.8 min) and CBD (8.3 min) are observed
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Figure 41: Chromatogram of CBDA after 3 hours of incubation with lysed P. putida.
CBDA (7.8 min) and CBD (8.3 min) are observed.

Figure 42: Chromatogram of CBDA after 4 hours of incubation with lysed P. putida.
CBDA (7.8) and CBD (8.3) are observed.
An autoclaved sample of the P. putida used as a control was assessed
concurrently with the active cell culture to be sure any observed conversion was, in fact,
produced by an enzyme present in the cell. Only CBDA was observed for all time points
with the control. The observation of the appearance of CBD suggests that Pseudomonas
putida has an enzyme which can convert the prodrug CBDA into the physiologically
active CBD. To calculate the rate at which this occurs, the area under the curve for CBD
was taken and calculations were performed in Excel using the volume of the injection (10
µL) and the molar mass of CBD (314.46 g/mol). The rate at which CBD appeared was
determined to be 5.0 nmol/hour.
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CHAPTER V
CONCLUSIONS
The first goal of this research was to isolate and identify CBDA from an extract
prepared in-house from Cannabis plant material. Isolating cannabinoids in-house from
plant material has several benefits for this research. The plant material itself is
considerably less expensive relative to the cost of a pure, isolated cannabinoid. Reagent
cost and a minimal on-hand quantity of the desired cannabinoid can hinder productive
research, thus having the ability to isolate CBDA lowers cost and increases efficiency.
In-house isolation also allows a more “green” approach because one is not required to use
extra resources to ship reagents and can monitor quality control.
A Soxhlet extraction was performed to obtain an extract which was high in
CBDA. The extract was then purified using a preparative HPLC method developed for
the separation of cannabinoids. The CBDA obtained from this method was seemingly
pure, as no other peaks were observed in the analytical HPLC chromatogram obtained
and few unidentifiable peaks were observed in the 1H- and 13C- NMR spectra. Other
cannabinoids could possibly be isolated with this method as well, however, CBDA was
the only pure cannabinoid isolated in this study. The development of this method will
allow further research to be conducted in our laboratory on various independently
isolated cannabinoids.
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The second goal of this research was to identify a cell line possessing enzymes
capable of decarboxylating CBDA. In its physiologically active form, cannabidiol is
supported by a vast body of literature as a potential cancer treatment. To accomplish this
goal, several cell lines were screened for CBDA decarboxylase activity by monitoring
conversion of CBDA to CBD via HPLC. An analytical HPLC method was successfully
developed for this task. Cell lines were selected based on the literature and previous
work in our research group with compounds which model cannabinoids (Cribbs, 2014).
The results indicate that a CBDA decarboxylase is present in Pseudomonas
putida. Cultures of P. putida which were not induced or induced with 2,4dihydroxybenzoate did not show any CBDA decarboxylase activity. However, cultures
of P. putida that were induced with salicylic acid for three days and lysed prior to
decarboxylase activity screening indicate the formation of CBD when incubated with
CBDA for at least three hours. This decarboxylase activity from P. putida is the first
enzymatic method for the decarboxylation of CBDA observed which does not require
substantial heat to convert it to its physiologically active form CBD.
If a cell line was identified, therapeutic drug development can move forward
using Cell-in-a-Box® technology. With the desired decarboxylation of CBDA to CBD
observed, isolation of the gene for the decarboxylation enzyme would be the next logical
step with cultures of P. putida which have been induced for three days with salicylic acid
and lysed. The isolated gene could then be inserted into a human embryonic kidney
(HEK) cell through genetic engineering. Once the HEK cell has been transfected with
the decarboxylase gene, it can be analyzed with the same assay developed for microbial
cells tested in this study, with the ultimate goal of encapsulating the HEK cells using
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Cell-in-a-Box® technology and testing in clinical trials. This could be especially
beneficial for patients with tumors which are difficult to remove surgically such as
gliomas, which CBD has been shown to treat effectively. The specific activity should
also be quantified because literature studies show that the effectiveness of CBD is dosedependent.
Future Research
The preparatory HPLC method could be developed further to not only isolate
CBDA but other major cannabinoids as well. The lack of purity of the other major
cannabinoids collected in this study meant that obtaining NMR data would not prove
useful for identification in this study. If the samples were pure, these could be collected
and used to identify compounds other than CBDA and THCA. Current standards could
also be spiked with standards to help identify unknown peaks in the current
chromatograms.
The procedure for collecting fractions would have to be optimized in order to
obtain compounds which are purer than those obtained in this study. This may be
achieved by reducing the time increment for collection or by altering the preparatory
HPLC parameters to achieve greater baseline separation between peaks. This could be
achieved by using a different organic component to manipulate the polarity of the mobile
phase. Acetonitrile could be substituted by a more polar solvent such as methanol which
may increase run length but could provide better resolution of peaks. Methanol is also
generally less expensive than acetonitrile with current prices from Sigma-Aldrich quoted
at $69.50 and $223.00, respectively, for 1 L of HPLC-grade reagents.
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The percent recovery of cannabidiolic acid could also be improved by minimizing
transfer steps in the sample processing once collected from the HPLC. The current
process requires evaporating the organic solvent and then back extracting from the
aqueous phase into pentane. If the number of steps in this process were able to be
reduced perhaps less CBDA would be lost in transfer and could increase the percent
recovery.
Additional decarboxylase assays could be done to find additional microbial
species capable of the decarboxylation of CBDA to CBD, with a focus on fungal species
to determine if there might be a species which catalyzes this reaction more efficiently.
The decarboxylase expressed by A. clavatus decarboxylates Category 1 substrates, those
which are the most similar to the structure of CBDA; however, there was difficulty in
homogenizing fungal samples when preparing them for assay. Work should be done with
current collaborators who prepare cell cultures to optimize this method and then
additional assays should be performed with cultures of different Aspergillus species such
as A. clavatus, A. giganteus, and A. longivesica which were reported by Snini et al.
(2013) to express the PatG gene. Another fungus which was not tested was
Trichosporon moniliform which decarboxylates salicylic acid and many other carboxylic
acids (Kirimura et al., 2010). Care needs to be taken in the initial stages of working with
these types of cells since there is a risk of fungal infection. The risks associated with
these types of cells should be mitigated by incorporating the gene for the decarboxylase
in a genetically-engineered human embryonic kidney cell.
If additional decarboxylase assays are in order, a standard curve should be made
in which CBDA and CBD are analyzed in tandem. This would assure that any effects
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observed from interaction of each analyte with each other could be observed. This would
also be a better application since they are not being analyzed individually in the context
of the enzymatic assay. A standard curve which matches the application would be more
beneficial than the current format of each individual standard curve.
Advancement in understanding of the therapeutic benefits of cannabinoids has
propelled the scientific community forward to develop a multitude of cannabinoid-based
therapies. A significant hurdle on the road to making the most beneficial medicine
available to the patients has been delivering the appropriate dose of cannabinoids in a
safe and effective matter. The results from this research provide an alternative to the
traditional mode of activating cannabinoid pro-drugs and a new way to potentially control
and monitor the effective dose of cannabinoids being administered.
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CONDITIONS FOR INDIVIDUAL CELL ASSAYS
FOR DECARBOXYLASE ACTIVITY
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Table 7: Conditions for Individual Cell Assays for Decarboxylase Activity
Intact or lysed

Induced

Length of
Induction

Wet Cell Mass (mg/mL)

Concentration of CBDA
(mg/mL)*

intact
lysed

None
None

N/A
N/A

72.8
72.8

10.0
10.0

Pseudomonas putida

intact
lysed
lysed
lysed
lysed
lysed
lysed
lysed
lysed
lysed
lysed
lysed

2,4-dihydroxybenzoate
2,4-dihydroxybenzoate
30 mM 2,4-dihydroxybenzoate
30 mM 2,4-dihydroxybenzoate
70 mM 2,4-dihydroxybenzoate
10 mM salicylic acid
10 mM salicylic acid
10 mM salicylic acid
10 mM salicylic acid
1 mM salicylic acid
1 mM salicylic acid
1 mM salicylic acid

1 day
3 days
1 day
3 days
1 day
3 days
3 days
3 days
3 days
3 days
3 days
3 days

40.4
40.4
133
69.5
78
68.4
23.6
Not provided
65.5
54.2
58.5
22.3

10.0
10.0
22.5
20.0
20.0
20.0
13.0
11.0
16.5
2.0
2.0
2.0

Klebsiella pneumonia

intact
intact
lysed
lysed
lysed
lysed

30 mM 2,4-dihydroxybenzoate
30 mM 2,4-dihydroxybenzoate
30 mM 2,4-dihydroxybenzoate
None
CBDA
30 mM 2,4-dihydroxybenzoate

3 days
3 days
3 days
N/A
1 day

162
62.4
74.4
84
55.2
42.4

22.5
23.0
23.0
12.7
12.7
15.0

Bacillus Subtilis

lysed
lysed
lysed
lysed
lysed
lysed

10 mM salicylic acid
40 mM salicylic acid
None
CBDA
None
4 mM salicylic acid

2 days
2 days
N/A
1 day
N/A
3 days

308.8
46
158
206.4
78.1
52.2

23.0
23.0
12.7
12.7
10.0
10.0

Aspergillus clavatus

lysed
lysed

4 mM salicylic acid
4 mM salicylic acid

3 days
3 days

Not provided
Not provided

10.0
10.0

Aspergillus niger

lysed

4 mM salicylic acid

3 days

Not provided

2.0

lysed
4 mM salicylic acid
lysed
4 mM salicylic acid
lysed
4 mM salicylic acid
*Stock solution in absolute ethanol added to incubation in total of 100 µL.

3 days
3 days
3 days

Not provided
Not provided
Not provided

2.0
13.5
11.0

Species
Enterobacter (Klebsiella)
aerogenes

Penicillium chrysogenum
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APPENDIX B
CHROMATOGRAMS OF FRACTIONS 2-6 COLLECTED
FROM THE PREPARATORY HPLC METHOD
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Additional Chromatograms Using the Analytical HPLC Method

Figure 43: Chromatogram of the residue recovered representing peak 2 in the preparatory
chromatogram. The sample was resuspended in 1.0 mL absolute ethanol and analyzed
using the analytical HPLC method.

Figure 44: Chromatogram of the residue recovered representing peak 3 in the preparatory
chromatogram. The sample was resuspended in 1.0 mL absolute ethanol and analyzed
using the analytical HPLC method.

Figure 45: Chromatogram of the residue recovered representing peak 4 in the preparatory
chromatogram. The sample was resuspended in 1.0 mL absolute ethanol and analyzed
using the analytical HPLC method.
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Figure 46: Chromatogram of the residue recovered representing peak 5 in the preparatory
chromatogram. The sample was resuspended in 1.0 mL absolute ethanol and analyzed
using the analytical HPLC method.

Figure 47: Chromatogram of the residue recovered representing peak 6 in the preparatory
chromatogram. The sample was resuspended in 1.0 mL absolute ethanol and analyzed
using the analytical HPLC method.
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APPENDIX C
REPRESENTATIVE HPLC CHROMATOGRAMS FOR
DECARBOXYLASE ACTIVITY IN
VARIOUS CELL LINES
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C1. Representative HPLC Chromoatograms for the Analysis of Bacillus subtilis
The following chromatograms were generated using an isocratic method of 30%
HPLC-grade water (solvent A) and 70% HPLC-grade methanol (solvent B).

Figure 48: Chromatogram after 0 hours of incubation of CBDA with lysed B. subtilis
induced with 40 mM salicylic acid.

Figure 49: Chromatogram after 1 hour of incubation of CBDA with lysed B. subtilis
induced with 40 mM salicylic acid.
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Figure 50: Chromatogram after 2 hours of incubation of CBDA with lysed B. subtilis
induced with 40 mM salicylic acid.

Figure 51: Chromatogram after 3 hours of incubation of CBDA with lysed B. subtilis
induced with 40 mM salicylic acid.

Figure 52: Chromatogram after 4 hours of incubation of CBDA with lysed B. subtilis
induced with 40 mM salicylic acid.
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Figure 53: Chromatogram after 0 hours of incubation of CBDA with lysed B. subtilis
induced with an unknown concentration of CBDA.

Figure 54: Chromatogram after 0.5 hour of incubation of CBDA with lysed B. subtilis
induced with an unknown concentration of CBDA.

Figure 55: Chromatogram after 1 hour of incubation of CBDA with lysed B. subtilis
induced with an unknown concentration of CBDA.
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Figure 56: Chromatogram after 2 hours of incubation of CBDA with lysed B. subtilis
induced with an unknown concentration of CBDA.
C2. Representative HPLC Chromoatograms for the Analysis of Enterobacter
(Klebsiella) aerogenes.

Figure 57: Chromatogram after 0 hours of incubation of CBDA with intact E. aerogenes.

Figure 58: Chromatogram after 0.5 hour of incubation of CBDA with intact E. aerogenes.
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Figure 59: Chromatogram after 1 hour of incubation of CBDA with intact E. aerogenes.

Figure 60: Chromatogram after 2 hours of incubation of CBDA with intact E. aerogenes.

Figure 61: Chromatogram after 3 hours of incubation of CBDA with intact E. aerogenes.
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Figure 62: Chromatogram after 0 hours of incubation of CBDA with lysed E. aerogenes.

Figure 63: Chromatogram after 0.5 hour of incubation of CBDA with lysed E. aerogenes.

Figure 64: Chromatogram after 1 hour incubation of CBDA with lysed E. aerogenes.
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Figure 65: Chromatogram after 2 hours of incubation of CBDA with lysed E. aerogenes

Figure 66: Chromatogram after 3 hours of incubation of CBDA with lysed E. aerogenes

105
C3. Representative HPLC Chromoatograms for the Analysis of Klebsiella
pneumonia
The following chromatograms were generated using an isocratic method of 25% HPLCgrade water (solvent A) and 75% HPLC-grade methanol (solvent B).

Figure 67: CBDA standard for K. pneumonia assay.

Figure 68: Chromatogram after 0 hour of incubation of CBDA with intact K. pneumonia
induced with 30 mM 2,4-dihydroxybenzoic acid for 3 days.
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Figure 69: Chromatogram after 0.5 hour of incubation of CBDA with intact K.
pneumonia induced with 30 mM 2,4-dihydroxybenzoic acid for 3 days.

Figure 70: Chromatogram after 1 hour of incubation of CBDA with intact K. pneumonia
induced with 30 mM 2,4-dihydroxybenzoic acid for 3 days.

Figure 71: Chromatogram after 2 hours of incubation of CBDA with intact K. pneumonia
induced with 30 mM 2,4-dihydroxybenzoic acid for 3 days.
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Figure 72: Chromatogram after 3 hours of incubation of CBDA with intact K. pneumonia
induced with 30 mM 2,4-dihydroxybenzoic acid for 3 days.

Figure 73: Chromatogram after 4 hours of incubation of CBDA with intact K. pneumonia
induced with 30 mM 2,4-dihydroxybenzoic acid for 3 days.
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C4. Representative HPLC Chromoatograms for the Analysis of Aspergillus clavatus
The following chromatograms were generated using an isocratic method of 25%
HPLC-grade water (solvent A) and 75% HPLC-grade methanol (solvent B).

Figure 74: Chromatogram after 0 hour of incubation of CBDA with lysed A. clavatus
Induced with 4 mM salicylic acid.

Figure 75: Chromatogram after 1 hour of incubation of CBDA with lysed A. clavatus
induced with 4 mM salicylic acid.
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Figure 76: Chromatogram after 2 hours of incubation of CBDA with lysed A. clavatus
induced with 4 mM salicylic acid.

Figure 77: Chromatogram after 3 hours of incubation of CBDA with lysed A. clavatus
induced with 4 mM salicylic acid.
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Figure 78: Chromatogram after 4 hours of incubation of CBDA with lysed A. clavatus
Induced with 4 mM salicylic acid.

111
C5. Representative HPLC Chromoatograms for the Analysis of Aspergillus niger
The following chromatograms were generated using an isocratic method of 25%
HPLC-grade water (solvent A) and 75% HPLC-grade methanol (solvent B).

Figure 79: Chromatogram after 0 hour of incubation of CBDA with lysed A. niger
induced with 4 mM salicylic acid.

Figure 80: Chromatogram after 1 hour of incubation of CBDA with lysed A. niger
induced with 4 mM salicylic acid.
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Figure 81: Chromatogram after 2 hours incubation of CBDA with lysed A. niger induced
with 4 mM salicylic acid.

Figure 82: Chromatogram after 3 hours of incubation of CBDA with lysed A. niger
induced with 4 mM salicylic acid.
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Figure 83: Chromatogram after 4 hours of incubation of CBDA with lysed A. niger
induced with 4 mM salicylic acid.
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C6. Representative HPLC Chromoatograms for the Analysis of Penicillium
chrysogenum
The following chromatograms were generated using an isocratic method of 25%
HPLC-grade water (solvent A) and 75% HPLC-grade methanol (solvent B).

Figure 84: Chromatogram after 0 hours of incubation of CBDA with lysed P.
chrysogenum induced with 4 mM salicylic acid.

Figure 85: Chromatogram after 1 hour of incubation of CBDA with lysed P.
chrysogenum induced with 4 mM salicylic acid.
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Figure 86: Chromatogram after 2 hours of incubation of CBDA with lysed P.
chrysogenum induced with 4 mM salicylic acid.

Figure 87: Chromatogram after 3 hours of incubation of CBDA with lysed P.
chrysogenum induced with 4 mM salicylic acid.
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Figure 88: Chromatogram after 4 hours of incubation of CBDA with lysed P.
chrysogenum induced with 4 mM salicylic acid.
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C7. Representative HPLC Chromoatograms for the Analysis of Pseudomonas putida

Figure 89: Chromatogram after 0 hour of incubation of CBDA with intact P. putida.
Induced 1 day with 30 mM 2,4-dihydroxybenzoic acid.

Figure 90: Chromatogram after 0.5 hour of incubation of CBDA with intact P. putida.
Induced 1 day with 30 mM 2,4-dihydroxybenzoic acid.

Figure 91: Chromatogram after 1 hour of incubation of CBDA with intact P. putida.
Induced 1 day with 30 mM 2,4-dihydroxybenzoic acid.

118

Figure 92: Chromatogram after 2 hours of incubation of CBDA with intact P. putida.
Induced 1 day with 30 mM 2,4-dihydroxybenzoic acid.

Figure 93: Chromatogram after 3 hours of incubation of CBDA with intact P. putida.
Induced 1 day with 30 mM 2,4-dihydroxybenzoic acid.

Figure 94: Chromatogram after 0 hour of incubation of CBDA with lysed P. putida.
Induced 3 days with 30 mM 2,4-dihydroxybenzoic acid.
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Figure 95: Chromatogram after 0.5 hour of incubation of CBDA with lysed P. putida.
Induced 3 days with 30 mM 2,4-dihydroxybenzoic acid.

Figure 96: Chromatogram after 1 hour of incubation of CBDA with lysed P. putida.
Induced 3 days with 30 mM 2,4-dihydroxybenzoic acid.

Figure 97: Chromatogram after 2 hours of incubation of CBDA with lysed P. putida.
Induced 3 days with 30 mM 2,4-dihydroxybenzoic acid.
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Figure 98: Chromatogram after 3 hours of incubation of CBDA with lysed P. putida
induced 3 days with 30 mM 2,4-dihydroxybenzoic acid.
The following chromatograms were generated according to the analytical procedure
outlined in Instrumentation of the Methodology section.

Figure 99: Chromatogram after 0 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.
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Figure 100: Chromatogram after 1 hour of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 101: Chromatogram after 2 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 102: Chromatogram after 3 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.
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Figure 103: Chromatogram after 4 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 104: Chromatogram after 5 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 105: Chromatogram after 6 hours of incubation of CBDA with lysed P. putida I
nduced with 10 mM salicylic acid.
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Figure 106: Chromatogram after 0 hour of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 107: Chromatogram after 1 hour of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 108: Chromatogram after 2 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.
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Figure 109: Chromatogram after 3 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 110: Chromatogram after 4 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 111: Chromatogram after 0 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.
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Figure 112: Chromatogram after 0.5 hour of incubation of CBDA with lysed P. putida.
Induced 3 days with 10 mM salicylic acid.

Figure 113: Chromatogram after 1 hour of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 114: Chromatogram after 2 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.
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Figure 115: Chromatogram after 3 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.

Figure 116: Chromatogram after 4 hours of incubation of CBDA with lysed P. putida
induced with 10 mM salicylic acid.
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APPENDIX D
RIGHTS AND PERMISSIONS FOR
USE OF FIGURES
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